Myelodysplastic syndrome differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(31 intermediate revisions by 5 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Myelodysplastic syndrome}}
[[Image:Home_logo1.png|right|250px|link=https://www.wikidoc.org/index.php/Myelodysplastic_syndrome]]
{{CMG}}
{{CMG}};{{AE}} {{HMHJ}} {{ZAS}} {{NM}} {{ADS}}
==Overview==
Myelodysplastic syndrome must be differentiated from other diseases that cause [[anemia]], [[neutropenia]], and [[thrombocytopenia]], such as: [[aplastic anemia]], [[fanconi anemia]], [[pure red cell aplasia]], [[Shwachman-Diamond syndrome]], [[paroxysmal nocturnal hemoglobinuria]], [[parvovirus B19|parovirus B19 infection]], and [[Vitamin B12|vitamin B12 defeciency]]
==Differentiating Myelodysplastic Syndrome from other Diseases==
'''ABBREVIATIONS'''
 
'''EPO''': Erythropoietin, '''FISH''': Fluorescence in situ hybridization, '''Hb''': Hemoglobin, '''LAD''': Leukocyte alkaline dehydrgenase, '''LAP''': Leukocyte alkaline phosphatase, '''LDH''': Lactate dehydrogenase, '''LFTs''': Liver function tests, '''NL''': Normal, '''PCR''': Polymerase chain reaction, '''Plt''': Platelet, '''PUD''': Peptic ulcer disease, '''RFTs''': Renal function tests, '''WBCs''': White blood cells.
{| class="wikitable"
! colspan="2" rowspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" + |Disease
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Clinical manifestations
! colspan="10" style="background:#4479BA; color: #FFFFFF;" align="center" + |Diagnosis
! rowspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" + |Other features
|-
! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" + |Symptoms
! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" + |Signs
! colspan="8" style="background:#4479BA; color: #FFFFFF;" align="center" + |CBC & Peripheral smear
! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" + |Bone marrow biopsy
! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" + |Other investigations
|-
! colspan="6" style="background:#4479BA; color: #FFFFFF;" align="center" + |WBCs
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Hb
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Plt
|-
! style="background:#4479BA; color: #FFFFFF;" align="center" + |WBC
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Blasts
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Left<br>shift
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Baso-<br>phils
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Eosino-<br>phils
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Mono-<br>cytes
|-
! colspan="2" |[[Myelodysplastic syndrome|Myelodysplastic syndromes]]<br>([[MDS]])<ref name="pmid24300826">{{cite journal |vauthors=Germing U, Kobbe G, Haas R, Gattermann N |title=Myelodysplastic syndromes: diagnosis, prognosis, and treatment |journal=Dtsch Arztebl Int |volume=110 |issue=46 |pages=783–90 |date=November 2013 |pmid=24300826 |pmc=3855821 |doi=10.3238/arztebl.2013.0783 |url=}}</ref><ref name="pmid26769228">{{cite journal |vauthors=Gangat N, Patnaik MM, Tefferi A |title=Myelodysplastic syndromes: Contemporary review and how we treat |journal=Am. J. Hematol. |volume=91 |issue=1 |pages=76–89 |date=January 2016 |pmid=26769228 |doi=10.1002/ajh.24253 |url=}}</ref>
|
* Constitutional
* [[Anemia]] related
* [[Bleeding]]
* [[Infection]]
|
* [[Pallor]]
* [[Petechiae]]
* [[Organomegaly]]
|[[Leukopenia|↓]]
|Variable
| -
|↓
|↓
|↓
|[[Anemia|↓]]
|[[Thrombocytopenia|↓]]
|
* Hypercellular/ normocellular [[bone marrow]] with [[Dysplastic change|dysplastic]] changes
|
* [[Cytogenetic analysis]]
* [[Flow cytometry]]
* Macro-ovalocytes
* Basophilic stippling
* [[Howell-Jolly body|Howell-Jolly body]]
|
* [[Leukemia]] transformation
* Acquired pseudo-Pelger-Huët anomaly
|-
! colspan="2" |[[Chronic myeloid leukemia]]<br>([[CML]])<ref name="pmid9012696">{{cite journal |vauthors=Savage DG, Szydlo RM, Goldman JM |title=Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period |journal=Br. J. Haematol. |volume=96 |issue=1 |pages=111–6 |date=January 1997 |pmid=9012696 |doi= |url=}}</ref><ref name="pmid26434969">{{cite journal |vauthors=Thompson PA, Kantarjian HM, Cortes JE |title=Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015 |journal=Mayo Clin. Proc. |volume=90 |issue=10 |pages=1440–54 |date=October 2015 |pmid=26434969 |pmc=5656269 |doi=10.1016/j.mayocp.2015.08.010 |url=}}</ref>
|
* Asymptomatic
* Constitutional
* [[Hyperviscosity]]  and/or [[anemia]] related
* [[Bleeding]]
* [[Infection]]
|
* [[Splenomegaly]]<br>(46–76%)
* [[Purpura]]
* [[Anemia]] related
* [[Priapism]]
|↑
|<2%
| +
|↑
|↑
|↑
|[[Anemia|↓]]
|NL
|
* Hypercellurarity with ↑ [[granuloscytosis]] and ↓ [[erythrocytosis]]
 
* [[Fibrosis]]
|
* [[FISH]] for t(9;22)(q34;q11.2)
* [[Reverse transcriptase]] quantitative [[PCR]] (RQ-PCR) for BCR-ABL
|
* [[Granulocytic]] [[dysplasia]] is minimal/absent
* May present with [[blast]] crisis
* Absolute [[leukocytosis]]  (median of 100,000/µL)
* Classic [[myelocyte]] bulge
* [[thrombocytopenia]] indicates advanced stage
|-
! colspan="2" |[[Polycythemia vera]]<br>([[PV]])<ref name="pmid29194068">{{cite journal |vauthors=Vannucchi AM, Guglielmelli P, Tefferi A |title=Polycythemia vera and essential thrombocythemia: algorithmic approach |journal=Curr. Opin. Hematol. |volume=25 |issue=2 |pages=112–119 |date=March 2018 |pmid=29194068 |doi=10.1097/MOH.0000000000000402 |url=}}</ref><ref name="pmid30252337">{{cite journal |vauthors=Pillai AA, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=30252337 |doi= |url=}}</ref><ref name="pmid30281843">{{cite journal |vauthors=Tefferi A, Barbui T |title=Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management |journal=Am. J. Hematol. |volume=94 |issue=1 |pages=133–143 |date=January 2019 |pmid=30281843 |doi=10.1002/ajh.25303 |url=}}</ref><ref name="pmid28028026">{{cite journal |vauthors=Rumi E, Cazzola M |title=Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms |journal=Blood |volume=129 |issue=6 |pages=680–692 |date=February 2017 |pmid=28028026 |pmc=5335805 |doi=10.1182/blood-2016-10-695957 |url=}}</ref>
|
* Constitutional
 
*  [[Thromboembolism]]<br>and [[bleeding]]
 
* [[Pruritus]] after<br>a warm bath
* [[PUD]] related
|
* Facial ruddiness
* Related to underlying cause
* [[Splenomegaly]]
* [[Renal]] [[bruit]]
|NL or ↑
|None
| -
|↑ or ↓
|NL or ↑
|NL
|↑↑
 
|NL
|
* Hypercellularity for age with tri-lineage growth
 
* [[Myelofibrosis]] (in up to 20% of patients)
|
* [[Radioisotope]] studies
* [[Serum]] [[EPO]] levels
* [[LFTs]]
* [[RFTs]]
* [[Imaging]] studies
* ↓ Serum [[ferritin]]
* ↓ [[Folate]] levels
* ↑↑ [[B12]] levels
|
* May transform into [[myelofibrosis]] or [[leukemia]]
|-
! colspan="2" |[[Primary myelofibrosis]] ([[PMF]])<ref name="pmid26891375">{{cite journal |vauthors=Cervantes F, Correa JG, Hernandez-Boluda JC |title=Alleviating anemia and thrombocytopenia in myelofibrosis patients |journal=Expert Rev Hematol |volume=9 |issue=5 |pages=489–96 |date=May 2016 |pmid=26891375 |doi=10.1586/17474086.2016.1154452 |url=}}</ref><ref>{{cite book | last = Hoffman | first = Ronald | title = Hematology : basic principles and practice | publisher = Elsevier | location = Philadelphia, PA | year = 2018 | isbn = 9780323357623 }}</ref><ref name="pmid16919893">{{cite journal |vauthors=Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W |title=Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF) |journal=Pathol. Biol. |volume=55 |issue=2 |pages=92–104 |date=March 2007 |pmid=16919893 |doi=10.1016/j.patbio.2006.06.002 |url=}}</ref><ref>{{cite book | last = Hoffman | first = Ronald | title = Hematology : basic principles and practice | publisher = Elsevier | location = Philadelphia, PA | year = 2018 | isbn = 9780323357623 }}</ref>
|
* Constitutional
* [[Anemia]] related
* [[Bleeding]]
* [[Infection]]
* [[Abdominal]] [[Pain]]
|
* [[Hepatosplenomegaly]]
* [[Petechiae]] & [[ecchymoses]]
* Abdominal distension
* [[Lymphadenopathy]]
|↓
|[[Erythroblasts]]
| -
|Absent
|NL
|NL
|[[Anemia|↓]]
|[[Thrombocytopenia|↓]]
|
* Variable with [[fibrosis]] or hypercellularity
|
* JAK2 mutation
* [[CALR]] [[mutation]]
* [[MPL]] [[mutation]]
* [[mutation|↑]] [[LAP]]
* [[mutation|↑]] [[LAD]]
* [[mutation|↑]] [[Uric acid]]
* [[mutation|↑]] [[B12]] levels
|
* [[Bone marrow]] aspiration shows a dry tap
* Variable with [[leukocytosis]] or [[leukopenia]]
|-
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Disease
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Symptoms
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Sign
! style="background:#4479BA; color: #FFFFFF;" align="center" + |WBC
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Blasts
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Left<br>shift
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Baso-<br>phils
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Eosino-<br>phils
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Mono-<br>cytes
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Hb
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Plt
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Bone marrow biopsy
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Other investigations
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Other features
|-
! colspan="2" |[[Essential thrombocythemia]] ([[ET]])<ref name="pmidhttp://dx.doi.org/10.1182/blood-2007-04-083501">{{cite journal| author=Schmoldt A, Benthe HF, Haberland G| title=Digitoxin metabolism by rat liver microsomes. | journal=Biochem Pharmacol | year= 1975 | volume= 24 | issue= 17 | pages= 1639-41 | pmid=http://dx.doi.org/10.1182/blood-2007-04-083501 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10  }} </ref><ref>{{Cite journal
| author = [[Daniel A. Arber]], [[Attilio Orazi]], [[Robert Hasserjian]], [[Jurgen Thiele]], [[Michael J. Borowitz]], [[Michelle M. Le Beau]], [[Clara D. Bloomfield]], [[Mario Cazzola]] & [[James W. Vardiman]]
| title = The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
| journal = [[Blood]]
| volume = 127
| issue = 20
| pages = 2391–2405
| year = 2016
| month = May
| doi = 10.1182/blood-2016-03-643544
| pmid = 27069254
}}</ref><ref>{{Cite journal
| author = [[A. Tefferi]], [[R. Fonseca]], [[D. L. Pereira]] & [[H. C. Hoagland]]
| title = A long-term retrospective study of young women with essential thrombocythemia
| journal = [[Mayo Clinic proceedings]]
| volume = 76
| issue = 1
| pages = 22–28
| year = 2001
| month = January
| doi = 10.4065/76.1.22
| pmid = 11155408
}}</ref>
|
* Headache
* [[Dizziness]]
* [[Visual]] disturbances
* [[Priapism]]
* Acute [[chest pain]]
|
* [[Splenomegaly]]
* [[Skin]] [[bruises]]
|
NL or ↑
|
None
| -
|
↓ or absent
|
NL
|
NL
|
[[Anemia|↓]]
|
↑↑
|
* Normal/Hypercellular
|
* [[JAK2]] [[mutation]]
* [[CALR]] [[mutation]]
* [[MPL]] [[mutation]]
|
* [[Thrombosis]]
* [[Hemorrhage]]
* [[Pregnancy]] loss
|-
! rowspan="4" |[[Myelodysplastic]]<br>/[[Myeloproliferative neoplasm|myeloproliferative<br>neoplasms]] (MDS/MPN)
![[Chronic myelomonocytic leukemia]] (CMML)<ref name="pmid27185207">{{cite journal |vauthors=Patnaik MM, Tefferi A |title=Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management |journal=Am. J. Hematol. |volume=91 |issue=6 |pages=631–42 |date=June 2016 |pmid=27185207 |doi=10.1002/ajh.24396 |url=}}</ref>
: <ref name="pmid22615103">{{cite journal |vauthors=Parikh SA, Tefferi A |title=Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management |journal=Am. J. Hematol. |volume=87 |issue=6 |pages=610–9 |date=June 2012 |pmid=22615103 |doi=10.1002/ajh.23203 |url=}}</ref><ref name="pmid25869097">{{cite journal |vauthors=Benton CB, Nazha A, Pemmaraju N, Garcia-Manero G |title=Chronic myelomonocytic leukemia: Forefront of the field in 2015 |journal=Crit. Rev. Oncol. Hematol. |volume=95 |issue=2 |pages=222–42 |date=August 2015 |pmid=25869097 |pmc=4859155 |doi=10.1016/j.critrevonc.2015.03.002 |url=}}</ref>
|
* Constitutional
* [[Anemia]] related
* [[Bleeding]]
* [[Infections]]
* [[Bone]] [[pain]]
* [[Leukemia Cutis]]
|
* [[Organomegaly]]
* [[Bruising]]
|↑
| < 20%
|
|NL
|[[Eosinophilia|↑]]
|↑↑
 
|[[Anemia|↓]]
|[[Thrombocytopenia|↓]]
|
* [[Myelodysplastic]] and [[myeloproliferative]] feature
|
* [[Cytogenetic analysis]]
* [[Flow cytometry]]
* ↑ [[LDH]]
|
* Overlapping of both, [[MDS]] and [[MPN]]
* Absolute [[monocytosis]] > 1 × 10<sup>9</sup>/L (defining feature)
 
* MD-CMML:[[WBC]] ≤ 13 × 10<sup>9</sup>/L (FAB)
 
*  MP-CMML:[[WBC]] > 13 × 10<sup>9</sup>/L (FAB)
 
|-
![[Atypical chronic myeloid leukemia]] (aCML), [[BCR/ABL|BCR-ABL]]1-<ref name="pmid26637732">{{cite journal |vauthors=Dao KH, Tyner JW |title=What's different about atypical CML and chronic neutrophilic leukemia? |journal=Hematology Am Soc Hematol Educ Program |volume=2015 |issue= |pages=264–71 |date=2015 |pmid=26637732 |pmc=5266507 |doi=10.1182/asheducation-2015.1.264 |url=}}</ref><ref name="pmid22289493">{{cite journal |vauthors=Muramatsu H, Makishima H, Maciejewski JP |title=Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions |journal=Semin. Oncol. |volume=39 |issue=1 |pages=67–73 |date=February 2012 |pmid=22289493 |pmc=3523950 |doi=10.1053/j.seminoncol.2011.11.004 |url=}}</ref>
|
*Asymptomatic
* Constitutional
* [[Hyperviscosity|Hyperviscosity]]  and/or [[anemia]] related
* [[Bleeding|Bleeding]]
* [[Infection|Infection]]
|
* [[Splenomegaly]]  (46–76%)
* [[Purpura]]
* [[Anemia]] related
* [[Priapism]]
|↑
|<20%
| +
|<2% of WBCs
|N/A
|N/A
|[[Anemia|↓]]
|[[Thrombocytopenia|↓]]
|
* Granulocytic [[hyperplasia]] with prominent [[dysplasia]]
|
* [[Cytogenetic analysis]]
* [[Flow cytometry]]
|
* Granulocytic [[dysplasia]] is prominent
* Absence of ''[[BCR/ABL|BCR-ABL]]'' or ''PDGFRA'', [[PDGFRB|''PDGFRB'',]] or ''[[FGFR1]]'' rearrangements
* [[WBC]] > 13 × 10<sup>9</sup>/L
|-
![[Juvenile myelomonocytic leukemia (patient information)|Juvenile myelomonocytic leukemia (]]JMML)<ref name="pmid9226148">{{cite journal |vauthors=Aricò M, Biondi A, Pui CH |title=Juvenile myelomonocytic leukemia |journal=Blood |volume=90 |issue=2 |pages=479–88 |date=July 1997 |pmid=9226148 |doi= |url=}}</ref><ref name="pmid80255132">{{cite journal |vauthors=Hasle H |title=Myelodysplastic syndromes in childhood--classification, epidemiology, and treatment |journal=Leuk. Lymphoma |volume=13 |issue=1-2 |pages=11–26 |date=March 1994 |pmid=8025513 |doi=10.3109/10428199409051647 |url=}}</ref>
|
* [[Infections]]
* [[Anemia]] related
|
* [[Hepatosplenomegaly]]
* [[Lymphadenopathy]]
* [[Rash]]
|[[Leukocytosis|↑]]
|↑
|N/A
|N/A
|N/A
|[[Monocytosis|↑]]
|[[Anemia|↓]]
|[[Thrombocytopenia|↓]]
|
* Hypercelluar with  ↑ [[myeloid cells]] in stages of maturation
|
* [[Cytogenetic analysis]]
* [[Flow cytometry]]
* [[Flow cytometry|↓]] [[Serum]] [[Iron]]
* [[Flow cytometry|↑]] [[Vitamin B12|B12]] levels
|
* Polyclonal [[hypergammaglobulinemia]]
|-
![[MDS]]/[[MPN]] with ring sideroblasts and [[thrombocytosis]] (MDS/MPN-RS-T)<ref name="pmid28188970">{{cite journal |vauthors=Patnaik MM, Tefferi A |title=Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management |journal=Am. J. Hematol. |volume=92 |issue=3 |pages=297–310 |date=March 2017 |pmid=28188970 |doi=10.1002/ajh.24637 |url=}}</ref><ref name="pmid30186759">{{cite journal |vauthors=Alshaban A, Padilla O, Philipovskiy A, Corral J, McAlice M, Gaur S |title=Lenalidomide induced durable remission in a patient with MDS/MPN-with ring sideroblasts and thrombocytosis with associated 5q- syndrome |journal=Leuk Res Rep |volume=10 |issue= |pages=37–40 |date=2018 |pmid=30186759 |doi=10.1016/j.lrr.2018.08.001 |url=}}</ref><ref name="pmid30524760">{{cite journal |vauthors=Bouchla A, Papageorgiou SG, Tsakiraki Z, Glezou E, Pavlidis G, Stavroulaki G, Bazani E, Foukas P, Pappa V |title=Plasmablastic Lymphoma in an Immunocompetent Patient with MDS/MPN with Ring Sideroblasts and Thrombocytosis-A Case Report |journal=Case Rep Hematol |volume=2018 |issue= |pages=2525070 |date=2018 |pmid=30524760 |pmc=6247723 |doi=10.1155/2018/2525070 |url=}}</ref>
|
* Constitutional
* [[Anemia]] related
* [[Thrombosis]]
 
|
* Variable
|NL or ↑
|NL
| -
|NL
|N/A
|N/A
|[[Anemia|↓]]
|[[Thrombocytosis|↑]]
|
* Hypercellularity with [[dyserythropoiesis]] and increased [[megakaryocytes]]
|
* [[Cytogenetic analysis]]
* [[Flow cytometry]]
* ↑ [[Serum]] [[Iron]]
|
* Large atypical [[megakaryocytes]]
 
* Ringed [[sideroblasts]]
* [[SF3B1]] [[mutation]]
|-
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Disease
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Symptoms
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Sign
! style="background:#4479BA; color: #FFFFFF;" align="center" + |WBC
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Blasts
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Left<br>shift
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Baso-<br>phils
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Eosino-<br>phils
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Mono-<br>cytes
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Hb
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Plt
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Bone marrow biopsy
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Other investigations
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Other features
|-
! colspan="2" |[[Chronic neutrophilic leukemia]] ([[CNL]])<ref name="pmid29440636">{{cite journal |vauthors=Szuber N, Tefferi A |title=Chronic neutrophilic leukemia: new science and new diagnostic criteria |journal=Blood Cancer J |volume=8 |issue=2 |pages=19 |date=February 2018 |pmid=29440636 |pmc=5811432 |doi=10.1038/s41408-018-0049-8 |url=}}</ref><ref name="pmid28028025">{{cite journal |vauthors=Maxson JE, Tyner JW |title=Genomics of chronic neutrophilic leukemia |journal=Blood |volume=129 |issue=6 |pages=715–722 |date=February 2017 |pmid=28028025 |pmc=5301820 |doi=10.1182/blood-2016-10-695981 |url=}}</ref><ref name="pmid26366092">{{cite journal |vauthors=Menezes J, Cigudosa JC |title=Chronic neutrophilic leukemia: a clinical perspective |journal=Onco Targets Ther |volume=8 |issue= |pages=2383–90 |date=2015 |pmid=26366092 |pmc=4562747 |doi=10.2147/OTT.S49688 |url=}}</ref>
|
* Asymptomatic
* Constitutional symptoms
* [[Bleeding]]
* [[Infection]]
|
* [[Splenomegaly]]
* [[Heptomegaly]]
* [[Purpura]]
* [[Anemia]] related
|↑
|Minimal
| +
|NL
|NL
|NL
|[[Anemia|↓]]
|[[Thrombocytopenia|↓]]
|
* Uniforme and intense hypercellularity with minimal to none [[fibrosis]]
* [[Neutrophil]] toxic granulations and [[Dohle bodies]]
|
* [[FISH]]
* Imaging for [[hepatosplenomegaly]]
* ↑  [[LDH]]
* ↑ [[B12]] levels
|
* Associationed with [[polycythemia vera]] and [[plasma cell disorders]]
* [[Leukocytosis]] with<br>[[chronic]] [[neutrophilia]]
|-
! colspan="2" |[[Chronic eosinophilic leukemia]],<br>not otherwise specified<br>(NOS)<ref name="pmid27512192">{{cite journal |vauthors=Vidyadharan S, Joseph B, Nair SP |title=Chronic Eosinophilic Leukemia Presenting Predominantly with Cutaneous Manifestations |journal=Indian J Dermatol |volume=61 |issue=4 |pages=437–9 |date=2016 |pmid=27512192 |pmc=4966405 |doi=10.4103/0019-5154.185716 |url=}}</ref><ref name="pmid29892549">{{cite journal |vauthors=Hofmans M, Delie A, Vandepoele K, Van Roy N, Van der Meulen J, Philippé J, Moors I |title=A case of chronic eosinophilic leukemia with secondary transformation to acute myeloid leukemia |journal=Leuk Res Rep |volume=9 |issue= |pages=45–47 |date=2018 |pmid=29892549 |pmc=5993353 |doi=10.1016/j.lrr.2018.04.001 |url=}}</ref><ref name="pmid23662039">{{cite journal |vauthors=Yamada Y, Rothenberg ME, Cancelas JA |title=Current concepts on the pathogenesis of the hypereosinophilic syndrome/chronic eosinophilic leukemia |journal=Transl Oncogenomics |volume=1 |issue= |pages=53–63 |date=2006 |pmid=23662039 |pmc=3642145 |doi= |url=}}</ref><ref name="pmid27722133">{{cite journal |vauthors=Kim TH, Gu HJ, Lee WI, Lee J, Yoon HJ, Park TS |title=Chronic eosinophilic leukemia with FIP1L1-PDGFRA rearrangement |journal=Blood Res |volume=51 |issue=3 |pages=204–206 |date=September 2016 |pmid=27722133 |doi=10.5045/br.2016.51.3.204 |url=}}</ref>
|
* Constitutional
* [[Rash]]
* [[Rhinitis]]
* [[Gastritis]]
* [[Thromboembolism]]<br>related
|
* [[Hypertension]]
* [[Eczema]], [[mucosal]] [[ulcers]], [[erythema]]
* [[Angioedema]]
 
* [[Ataxia]]
* [[Anemia]]
* [[Lymphadenopathy]]
* [[Hepatosplenomegaly]]
|[[Leukocytosis|↑]]
|Present
| +
|↑
|↑↑
|↑
|[[Anemia|↓]]
|[[Thrombocytopenia|↓]]
|
* Hypercelluar with  ↑ [[eosinophilic]] precursors, ↑ [[eosinophils]], and atypical [[mononuclear cells]]
|
* [[FISH]]
* Cytogenetic analysis of purified [[eosinophils]] and [[X-chromosome]] inactivation analysis
* ↑ [[B12]] levels
* ↑ [[LDH]]
|
* [[Heart failure]] [[Lung fibrosis]]
* [[Encephalopathy]]
* [[Erythema annulare centrifugam]]
|-
! colspan="2" |[[Myeloproliferative neoplasm|MPN]],<br>unclassifiable
|
*Similar to other<br>[[Myeloproliferative neoplasm|myeloproliferative neoplasms]]
|
*Similar to other<br>[[Myeloproliferative neoplasm|myeloproliferative neoplasms]]
|[[Leukocytosis|↑]]
|Variable
|↑ or ↓
|↑ or ↓
|↑ or ↓
|↓
|↑
|
* ↑ [[megakaryocyte]] proliferation with variable hypercellularity in [[granulocytic]] or [[erythrocytic]] cell lines
|
* May resemble other<br>[[myeloproliferative neoplasms]]
|
*Similar to other [[myeloprolifeartive neoplasms]] but do not fulfil the criteria to be classified to a specific type
|-
! colspan="2" |[[Mastocytosis]]<ref name="pmid24262698">{{cite journal |vauthors=Carter MC, Metcalfe DD, Komarow HD |title=Mastocytosis |journal=Immunol Allergy Clin North Am |volume=34 |issue=1 |pages=181–96 |date=February 2014 |pmid=24262698 |pmc=3863935 |doi=10.1016/j.iac.2013.09.001 |url=}}</ref><ref name="pmid29494109">{{cite journal |vauthors=Macri A, Cook C |title= |journal= |volume= |issue= |pages= |date= |pmid=29494109 |doi= |url=}}</ref><ref name="pmid25031064">{{cite journal |vauthors=Lladó AC, Mihon CE, Silva M, Galzerano A |title=Systemic mastocytosis - a diagnostic challenge |journal=Rev Bras Hematol Hemoter |volume=36 |issue=3 |pages=226–9 |date=2014 |pmid=25031064 |pmc=4109736 |doi=10.1016/j.bjhh.2014.03.003 |url=}}</ref><ref name="pmid28031180">{{cite journal |vauthors=Valent P, Akin C, Metcalfe DD |title=Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts |journal=Blood |volume=129 |issue=11 |pages=1420–1427 |date=March 2017 |pmid=28031180 |pmc=5356454 |doi=10.1182/blood-2016-09-731893 |url=}}</ref>
|
* Constitutional
 
* [[Pruritus]] & [[Flushing]]
* [[Urticaria]] & [[Blisters]]
 
* [[Hypotension]] & [[PUD]]
* [[Bleeding]]
* [[Bronchoconstriction]]


==Overview==
|
The differential diagnosis is that of [[anemia]], [[thrombocytopenia]], and/or [[leukopenia]].  Usually, the elimination of known [[etiologies]] of [[cytopenias]], along with a dysplastic bone marrow, is required to diagnose a myelodysplastic syndrome.
* [[Mastocytosis exanthema]]
* [[Blistering]]
* [[Swelling]]
* [[Lymphadenopathy]]
* [[Bleeding]]
* [[Fibrosis]]
|[[Leukocytosis|↑]]
|None
| -
|NL
|[[Eosinophilia|↑]]
|NL
|[[Anemia|↓]]
|↓ or ↑
|
* Multifocal dense infiltrates of [[mast cells]] with atypical [[morphology]] in >25 %
|
* Cytogenetic analysis for [[c-KIT]] [[receptor]] [[mutations]]
* [[Serum]] [[tryptase]] levels
* 24-hour urine test for N-methyl [[histamine]] and 11-beta-[[prostaglandine]]
* ↑ [[Alkaline phosphatase]]
* ↑ [[LDH]]
|
* Skin most commonly involved
* Susceptibility to [[anaphylaxix]]
* [[Osteoporosis]]
|-
! colspan="2" |[[Myeloid]]/[[lymphoid]] [[neoplasms]]<br>with [[eosinophilia]] and rearrangement<br>of [[PDGFR|PDGFRA]], [[PDGFRB]], or [[FGFR1]],<br>or with [[PCM1]]-[[JAK2]]<ref name="KumarChen2015">{{cite journal|last1=Kumar|first1=Kirthi R.|last2=Chen|first2=Weina|last3=Koduru|first3=Prasad R.|last4=Luu|first4=Hung S.|title=Myeloid and Lymphoid Neoplasm With Abnormalities of FGFR1 Presenting With Trilineage Blasts and RUNX1 Rearrangement|journal=American Journal of Clinical Pathology|volume=143|issue=5|year=2015|pages=738–748|issn=1943-7722|doi=10.1309/AJCPUD6W1JLQQMNA}}</ref><ref>{{Cite journal
| author = [[Paolo Strati]], [[Guilin Tang]], [[Dzifa Y. Duose]], [[Saradhi Mallampati]], [[Rajyalakshmi Luthra]], [[Keyur P. Patel]], [[Mohammad Hussaini]], [[Abu-Sayeef Mirza]], [[Rami S. Komrokji]], [[Stephen Oh]], [[John Mascarenhas]], [[Vesna Najfeld]], [[Vivek Subbiah]], [[Hagop Kantarjian]], [[Guillermo Garcia-Manero]], [[Srdan Verstovsek]] & [[Naval Daver]]
| title = Myeloid/lymphoid neoplasms with FGFR1 rearrangement
| journal = [[Leukemia & lymphoma]]
| volume = 59
| issue = 7
| pages = 1672–1676
| year = 2018
| month = July
| doi = 10.1080/10428194.2017.1397663
| pmid = 29119847
}}</ref><ref>{{Cite journal
| author = [[Ximena Montenegro-Garreaud]], [[Roberto N. Miranda]], [[Alexandra Reynolds]], [[Guilin Tang]], [[Sa A. Wang]], [[Mariko Yabe]], [[Wei Wang]], [[Lianghua Fang]], [[Carlos E. Bueso-Ramos]], [[Pei Lin]], [[L. Jeffrey Medeiros]] & [[Xinyan Lu]]
| title = Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase
| journal = [[Human pathology]]
| volume = 65
| pages = 147–156
| year = 2017
| month = July
| doi = 10.1016/j.humpath.2017.05.008
| pmid = 28551329
}}</ref><ref>{{Cite journal
| author = [[Paola Villafuerte-Gutierrez]], [[Montserrat Lopez Rubio]], [[Pilar Herrera]] & [[Eva Arranz]]
| title = A Case of Myeloproliferative Neoplasm with BCR-FGFR1 Rearrangement: Favorable Outcome after Haploidentical Allogeneic Transplantation
| journal = [[Case reports in hematology]]
| volume = 2018
| pages = 5724960
| year = 2018
| month =
| doi = 10.1155/2018/5724960
| pmid = 30647980
}}</ref>
|
* Asymptomatic
* Constitutional
* [[Rash]]
* [[Cough]] & breathlessness
* [[Peripheral neuropathy]]/<br>[[encephalopathy]]
|
* [[Fever]]
* [[Lymphadenopathy]]
| ↑
| NL
| -
| NL
| [[Eosinophilia|↑]]
|[[Monocytosis|↑]]
| NL
| [[Thrombocytopenia|↓]]
|
* [[Myeloid]] expansion with [[eosinophilia]]
|
* [[FISH]] shows t(8;13) and t(8;22)
|
* May present or evolve into [[acute myeloid]] or [[lymphoblastic leukemia]]
* [[Leukocytosis]] (30 - 59 × 10<sup>9</sup>/L
|-
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Disease
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Symptoms
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Sign
! style="background:#4479BA; color: #FFFFFF;" align="center" + |WBC
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Blasts
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Left<br>shift
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Baso-<br>phils
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Eosino-<br>phils
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Mono-<br>cytes
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Hb
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Plt
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Bone marrow biopsy
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Other investigations
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Other features
|-
! colspan="2" |B-lymphoblastic leukemia/lymphoma<ref name="pmid30107017">{{cite journal |vauthors=Kamiya-Matsuoka C, Garciarena P, Amin HM, Tremont-Lukats IW, de Groot JF |title=B lymphoblastic leukemia/lymphoma presenting as seventh cranial nerve palsy |journal=Neurol Clin Pract |volume=3 |issue=6 |pages=532–534 |date=December 2013 |pmid=30107017 |pmc=6082360 |doi=10.1212/CPJ.0b013e3182a78ef0 |url=}}</ref><ref name="pmid29029550">{{cite journal |vauthors=Zhang X, Rastogi P, Shah B, Zhang L |title=B lymphoblastic leukemia/lymphoma: new insights into genetics, molecular aberrations, subclassification and targeted therapy |journal=Oncotarget |volume=8 |issue=39 |pages=66728–66741 |date=September 2017 |pmid=29029550 |pmc=5630450 |doi=10.18632/oncotarget.19271 |url=}}</ref>
|
* Constitutional
* [[Anemia]] related
* [[Bleeding]]
* [[Infection]]
* [[Bone pain]]
|
* [[Pallor]]
* [[Petechiae]]
* [[Organomegaly]]
* [[Lymphadenopathy]]
|NL or ↑
|>25%
|N/A
|↑ or ↓
|↑ or ↓
|↑ or ↓
|[[Anemia|↓]]
|[[Thrombocytopenia|↓]]
|
* Hypercellular with [[blast]] infilterationwith or without [[myelodysplasia]]
|
* [[Cytogenetic analysis]]
* [[Flow cytometry]]
 
* [[FISH]]
* [[Auer rod|Auer bodies]]
|
* May present as [[Extramedullary myeloid tumor|extramedullary]] disease ([[Extramedullary Myeloid Cell Tumor|Myeloid sarcoma]])
|-
! colspan="2" |[[Acute myeloid leukemia]] ([[AML]])<br>and related [[neoplasms]]<ref name="pmid3864727">{{cite journal |vauthors=Islam A, Catovsky D, Goldman JM, Galton DA |title=Bone marrow biopsy changes in acute myeloid leukaemia. I: Observations before chemotherapy |journal=Histopathology |volume=9 |issue=9 |pages=939–57 |date=September 1985 |pmid=3864727 |doi= |url=}}</ref><ref name="pmid17587881">{{cite journal |vauthors=Orazi A |title=Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases |journal=Pathobiology |volume=74 |issue=2 |pages=97–114 |date=2007 |pmid=17587881 |doi=10.1159/000101709 |url=}}</ref>
|
* Constitutional
* [[Anemia]] related
* [[Bleeding|Bleeding]]
* [[Bone pain|Bone pain]]
* [[Joint pain|Joint pain]]
* [[Infections|Infections]]
|
* [[Infection]] related
 
* [[Pallor|Pallor]]
* [[Chloroma|Leukemia cutis]]
* [[Bruising]] & [[Petechia|petechiae]]
* [[Lymphadenopathy]]
 
* [[Hepatomegaly|Hepatosplenomegaly]]
|NL or ↑
|↑
|N/A
|↑ or ↓
|↑ or ↓
|↑ or ↓
|[[Anemia|↓]]
|[[Thrombocytopenia|↓]]
|
* Increased  immature[[myeloid]] [[cells]]
with [[Dysplastic change|dysplasia]]     
|
* [[Cytogenetic analysis]]
* [[Flow cytometry]]
* [[FISH]]
* ↑ [[Potassium]]
* ↑ [[Uric acid]]
* ↑ [[Phosphorus]]
* ↓ [[Calcium]]
* ↑ [[LDH]]
|
* Common in [[Down syndrome]]
|-
! colspan="2" |[[Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid<br>dendritic cell neoplasm]]<ref>{{Cite journal
| author = [[F. Julia]], [[T. Petrella]], [[M. Beylot-Barry]], [[M. Bagot]], [[D. Lipsker]], [[L. Machet]], [[P. Joly]], [[O. Dereure]], [[M. Wetterwald]], [[M. d'Incan]], [[F. Grange]], [[J. Cornillon]], [[G. Tertian]], [[E. Maubec]], [[P. Saiag]], [[S. Barete]], [[I. Templier]], [[F. Aubin]] & [[S. Dalle]]
| title = Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients
| journal = [[The British journal of dermatology]]
| volume = 169
| issue = 3
| pages = 579–586
| year = 2013
| month = September
| doi = 10.1111/bjd.12412
| pmid = 23646868
}}</ref><ref>{{Cite journal
| author = [[Livio Pagano]], [[Caterina Giovanna Valentini]], [[Alessandro Pulsoni]], [[Simona Fisogni]], [[Paola Carluccio]], [[Francesco Mannelli]], [[Monia Lunghi]], [[Gianmatteo Pica]], [[Francesco Onida]], [[Chiara Cattaneo]], [[Pier Paolo Piccaluga]], [[Eros Di Bona]], [[Elisabetta Todisco]], [[Pellegrino Musto]], [[Antonio Spadea]], [[Alfonso D'Arco]], [[Stefano Pileri]], [[Giuseppe Leone]], [[Sergio Amadori]] & [[Fabio Facchetti]]
| title = Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study
| journal = [[Haematologica]]
| volume = 98
| issue = 2
| pages = 239–246
| year = 2013
| month = February
| doi = 10.3324/haematol.2012.072645
| pmid = 23065521
}}</ref><ref>{{Cite journal
| author = [[Joseph D. Khoury]]
| title = Blastic Plasmacytoid Dendritic Cell Neoplasm
| journal = [[Current hematologic malignancy reports]]
| volume = 13
| issue = 6
| pages = 477–483
| year = 2018
| month = December
| doi = 10.1007/s11899-018-0489-z
| pmid = 30350260
}}</ref><ref>{{Cite journal
| author = [[Shinichiro Sukegawa]], [[Mamiko Sakata-Yanagimoto]], [[Ryota Matsuoka]], [[Haruka Momose]], [[Yusuke Kiyoki]], [[Masayuki Noguchi]], [[Naoya Nakamura]], [[Rei Watanabe]], [[Manabu Fujimoto]], [[Yasuhisa Yokoyama]], [[Hidekazu Nishikii]], [[Takayasu Kato]], [[Manabu Kusakabe]], [[Naoki Kurita]], [[Naoshi Obara]], [[Yuichi Hasegawa]] & [[Shigeru Chiba]]
| title = &#91;Blastic plasmacytoid dendritic cell neoplasm accompanied by chronic myelomonocytic leukemia successfully treated with azacitidine&#93;
| journal = <nowiki>[[[Rinsho ketsueki] The Japanese journal of clinical hematology]]</nowiki>
| volume = 59
| issue = 12
| pages = 2567–2573
| year = 2018
| month =
| doi = 10.11406/rinketsu.59.2567
| pmid = 30626790
}}</ref>
|
* [[Cutaneous]] symptoms (brown/purple nodular lesions) on [[face]], [[scalp]], [[lower limb]] & [[trunk]]
|
* Brown/violaceous [[bruise]] like lesions
* [[Lymphadenopathy]]
* [[Splenomegaly]]
| NL
| ↑
|
|NL
| NL
| NL
| [[Anemia|↓]]
| [[Thrombocytopenia|↓]]
|
* [[Malignant|Malignant cells]]
|
* [[Immunohistochemistry]] or [[flow cytometry]] for [[CD4]] & [[CD56]]
* [[Neutropenia]]
|
* TdT expression positive
* May develop [[chronic myelomonocytic leukemia]] (CMML)
|-
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Disease
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Symptoms
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Sign
! style="background:#4479BA; color: #FFFFFF;" align="center" + |WBC
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Blasts
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Left<br>shift
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Baso-<br>phils
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Eosino-<br>phils
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Mono-<br>cytes
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Hb
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Plt
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Bone marrow biopsy
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Other investigations
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Other features
|-
! rowspan="3" |T-lymphoblastic leukemia/<br>lymphoma
*
*
!T-lymphoblastic leukemia/<br>lymphoma<ref name="pmid26276771">{{cite journal |vauthors=You MJ, Medeiros LJ, Hsi ED |title=T-lymphoblastic leukemia/lymphoma |journal=Am. J. Clin. Pathol. |volume=144 |issue=3 |pages=411–22 |date=September 2015 |pmid=26276771 |doi=10.1309/AJCPMF03LVSBLHPJ |url=}}</ref><ref name="pmid19284608">{{cite journal |vauthors=Patel KJ, Latif SU, de Calaca WM |title=An unusual presentation of precursor T cell lymphoblastic leukemia/lymphoma with cholestatic jaundice: case report |journal=J Hematol Oncol |volume=2 |issue= |pages=12 |date=March 2009 |pmid=19284608 |pmc=2663564 |doi=10.1186/1756-8722-2-12 |url=}}</ref><ref name="pmid24822133">{{cite journal |vauthors=Elreda L, Sandhu M, Sun X, Bekele W, Cohen AJ, Shah M |title=T-cell lymphoblastic leukemia/lymphoma: relapse 16 years after first remission |journal=Case Rep Hematol |volume=2014 |issue= |pages=359158 |date=2014 |pmid=24822133 |pmc=4005062 |doi=10.1155/2014/359158 |url=}}</ref>
|
* Constitutional
* [[Anemia]] Related
* [[Bleeding]]
* [[Superior vena cava syndrome]]
|
* [[Lymphadenopathy]]
* [[Mediastinal mass]]
*  [[Pleural effusions]]
* [[Trachea|Tracheal]] obstruction
* [[Pericardial effusions]]
|↑
|>25% [[Blast|blasts]] ([[Leukemia]])
 
<25% [[Blast|blasts]] ([[Lymphoma]])
|↑ or ↓
|↑ or ↓
|↑ or ↓
|↓
|↓
|
* Hypercelluarity with increased [[T cells]] precursors
|
* [[Cytogenetic analysis]][[Flow cytometry]]
* [[FISH]]
* ↑ [[LDH]]
* Positive for TdT
|
* May involve [[brain]], [[skin]], and [[testes]].
|-
!Provisional entity: Natural killer (NK) cell lymphoblastic leukemia/lymph<ref name="pmid28868017">{{cite journal |vauthors=Sedick Q, Alotaibi S, Alshieban S, Naheet KB, Elyamany G |title=Natural Killer Cell Lymphoblastic Leukaemia/Lymphoma: Case Report and Review of the Recent Literature |journal=Case Rep Oncol |volume=10 |issue=2 |pages=588–595 |date=2017 |pmid=28868017 |doi=10.1159/000477843 |url=}}</ref>
|
* Constitutional
* [[Anemia]] Related
* [[Bleeding]]
* [[Superior vena cava syndrome]]
|
* [[Lymphadenopathy]]
* [[Mediastinal mass]]
*  [[Pleural effusions]]
* [[Trachea|Tracheal]] obstruction
* [[Pericardial effusions]]
|↑
|↑
|↑ or ↓
|↑ or ↓
|↑ or ↓
|↓
|↓
|
* N/A
|
* [[Cytogenetic analysis]]
 
* [[FISH]]
* [[Flow cytometry]]
* ↑ [[LDH]]
|
* Similar to [[T-cell]] lymphoblastic [[leukemia]] but may have more aggressive clinical course.
* [[Diagnosis]] is usually based on presence of [[CD56]] expression, and  [[T-cell]]-associated markers such as [[CD2]] and [[CD7]].
*  [[B cell|B-cell]] markers are absent.
|-
!Provisional entity: Early T-cell precursor lymphoblastic leukemia<ref name="pmid26747249">{{cite journal |vauthors=Jain N, Lamb AV, O'Brien S, Ravandi F, Konopleva M, Jabbour E, Zuo Z, Jorgensen J, Lin P, Pierce S, Thomas D, Rytting M, Borthakur G, Kadia T, Cortes J, Kantarjian HM, Khoury JD |title=Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype |journal=Blood |volume=127 |issue=15 |pages=1863–9 |date=April 2016 |pmid=26747249 |pmc=4915808 |doi=10.1182/blood-2015-08-661702 |url=}}</ref><ref name="pmid23695450">{{cite journal |vauthors=Haydu JE, Ferrando AA |title=Early T-cell precursor acute lymphoblastic leukaemia |journal=Curr. Opin. Hematol. |volume=20 |issue=4 |pages=369–73 |date=July 2013 |pmid=23695450 |pmc=3886681 |doi=10.1097/MOH.0b013e3283623c61 |url=}}</ref>
|
* Constitutional
* [[Anemia]] Related
* [[Bleeding]]
* [[Superior vena cava syndrome]]
|
* [[Lymphadenopathy]]
* [[Mediastinal mass]]
*  [[Pleural effusions]]
* [[Trachea|Tracheal]] obstruction
* [[Pericardial effusions]]
|↑
|↑
|↑ or ↓
|↑ or ↓
|↑ or ↓
|↓
|↓
|
* Hypercelluarity with increased [[T cells]] precursors
|
* [[Cytogenetic analysis]]
* [[FISH]]
* [[Flow cytometry]]
* ↑ [[LDH]]
|
* Similar to [[T cell|T-cell]] lymphoblastic [[leukemia]] but is more aggressive clinically and cell are characterized by [[Flow cytometry|cytometry]] as [[CD1a]]<sup>−</sup>, [[CD8]]<sup>−</sup>, [[CD5]]<sup>−</sup> (dim), and positivity for 1 or more stem cell or [[myeloid]] [[antigens]].
* [[Gene expression]] indicates more immature [[cells]] as compared to other subtypes of [[T cell|T-cell]] [[neoplasms]].
|}
 
===Differentiating myelodysplastic syndrome from other causes of macrocytic anemia===
{|
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Disease
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Genetics
! colspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestation
! colspan="12" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab findings
|-
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Signs
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hemolysis
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Intrinsic/Extrinsic
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hb concentration
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |MCV
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |RDW
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Reticulocytosis
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Haptoglobin levels
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hepcidin
! colspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Iron studies
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Specific finding on blood smear
|-
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Serum iron
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Serum Tfr level
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Transferrin or TIBC
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Ferritin
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | Transferrin saturation
|-
! align="center" style="background:#DCDCDC;" |[[Folate deficiency]]<ref name="pmid25663227">{{cite journal |vauthors=Koike H, Takahashi M, Ohyama K, Hashimoto R, Kawagashira Y, Iijima M, Katsuno M, Doi H, Tanaka F, Sobue G |title=Clinicopathologic features of folate-deficiency neuropathy |journal=Neurology |volume=84 |issue=10 |pages=1026–33 |date=March 2015 |pmid=25663227 |doi=10.1212/WNL.0000000000001343 |url=}}</ref>
| align="left" style="background:#F5F5F5;" |
* Impaired [[DNA]] synthesis
| align="left" style="background:#F5F5F5;" |
* [[Long-term effects of alcohol|Alcohol consumption]]
* History of using drugs like [[methotrexate]], [[trimethoprim]], and [[phenytoin]]
* Low socioeconomic groups with poor nutrition
* Older people
* [[Pregnancy|Pregnant]] and [[lactating]] women
| align="left" style="background:#F5F5F5;" |
* No neurological symptoms vs [[Vitamin B12 deficiency|B12 deficiency]]
* [[Odinophagia|Odynophagia]]
* [[Stomatitis|Angular stomatitis]]
| align="left" style="background:#F5F5F5;" |
* [[Glossitis]]
* Signs of [[Congestive heart failure|heart failure]]
* [[Anencephaly]] and [[spina bifida]]
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |Anisochromic
| align="center" style="background:#F5F5F5;" |[[Macrocytic anemia|Macrocytic]]
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↓
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↓
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="left" style="background:#F5F5F5;" |
* [[Macrocytosis|RBC macrocytosis]]
* [[Neutrophil|Hypersegmented neutrophils]]
* [[Pancytopenia]] in severe cases
*
|-
! align="center" style="background:#DCDCDC;" |[[Vitamin B12 deficiency]]<ref name="pmid25189324">{{cite journal |vauthors=Hunt A, Harrington D, Robinson S |title=Vitamin B12 deficiency |journal=BMJ |volume=349 |issue= |pages=g5226 |date=September 2014 |pmid=25189324 |doi= |url=}}</ref>
| align="left" style="background:#F5F5F5;" |
* Impaired [[DNA synthesis]]
| align="left" style="background:#F5F5F5;" |
* [[Pernicious anemia]]
* [[Crohn's disease]]
* [[Gastrectomy]]
* [[Vegan|Veganism]]
* [[Diphyllobothrium|Diphyllobothrium latum]] infection
| align="left" style="background:#F5F5F5;" |
* [[Psychosis]]
* [[Insomnia]]
* [[Depression]]
* Cognitive slowing
* [[Restless leg syndrome]]
| align="left" style="background:#F5F5F5;" |
* Neurological deficit
* [[Myelopathy]]
* [[Memory loss]] with reduced attention span
* [[Nystagmus]]
* Positive [[Romberg test|romberg sign]]
* Positive [[Lhermitte's sign]]
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |Anisochromic
| align="center" style="background:#F5F5F5;" |[[Macrocytic anemia|Macrocytic]]
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↓
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↓
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="left" style="background:#F5F5F5;" |
* [[Senile]] [[neutrophil]]
* [[Anisocytosis]]
* [[Ovalocytosis|Ovalocytes]]
|-
! align="center" style="background:#DCDCDC;" |[[Orotic aciduria]]<ref name="pmid25757096">{{cite journal |vauthors=Grohmann K, Lauffer H, Lauenstein P, Hoffmann GF, Seidlitz G |title=Hereditary orotic aciduria with epilepsy and without megaloblastic anemia |journal=Neuropediatrics |volume=46 |issue=2 |pages=123–5 |date=April 2015 |pmid=25757096 |doi=10.1055/s-0035-1547341 |url=}}</ref>
| align="left" style="background:#F5F5F5;" |
* [[Autosomal recessive]]
* Deficiency of enzyme [[Uridine monophosphate synthetase|UMPS]]
| align="left" style="background:#F5F5F5;" |
* Episodic [[Nausea and vomiting|vomiting]]
* [[Rhabdomyolysis]]
| align="left" style="background:#F5F5F5;" |
* [[Coma]]
* [[Gastrointestinal tract|Gastrointestinal]] manifestation
| align="left" style="background:#F5F5F5;" |
* Neurological manifestation
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |Anisochromic
| align="center" style="background:#F5F5F5;" |[[Macrocytic anemia|Macrocytic]]
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↓
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↓
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |NA
|-
! align="center" style="background:#DCDCDC;" |[[Fanconi anemia]]<ref name="pmid25455269">{{cite journal |vauthors=Alter BP |title=Fanconi anemia and the development of leukemia |journal=Best Pract Res Clin Haematol |volume=27 |issue=3-4 |pages=214–21 |date=2014 |pmid=25455269 |pmc=4254647 |doi=10.1016/j.beha.2014.10.002 |url=}}</ref>
| align="left" style="background:#F5F5F5;" |
* [[Autosomal recessive]]
* [[X-linked recessive]]
| align="left" style="background:#F5F5F5;" |
* History of [[anemia]] at age 16
| align="left" style="background:#F5F5F5;" |
* [[Hypopigmentation]]
* [[Café au lait spot|Cafe-au-lait patches]]
* Radial ray anomaly
| align="left" style="background:#F5F5F5;" |
* Significant for bilateral short thumbs
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |Anisochromic
| align="center" style="background:#F5F5F5;" |[[Macrocytic anemia|Macrocytic]]
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↓
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↓
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="left" style="background:#F5F5F5;" |
* Nl appearing [[White blood cells|WBC]], [[Red blood cell|RBC]] and [[Platelet|Platelets]]
* But the number is greatly reduced
|-
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Disease
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Genetics
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Signs
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hemolysis
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Intrinsic/Extrinsic
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hb concentration
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |MCV
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |RDW
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Reticulocytosis
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Haptoglobin levels
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hepcidin
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Serum iron
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Serum Tfr level
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |IBC
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Ferritin
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Transferrin saturation
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Specific finding on blood smear
|-
! align="center" style="background:#DCDCDC;" |[[Diamond-Blackfan anemia]]<ref name="pmid24665981">{{cite journal |vauthors=Vlachos A, Blanc L, Lipton JM |title=Diamond Blackfan anemia: a model for the translational approach to understanding human disease |journal=Expert Rev Hematol |volume=7 |issue=3 |pages=359–72 |date=June 2014 |pmid=24665981 |doi=10.1586/17474086.2014.897923 |url=}}</ref>
| align="left" style="background:#F5F5F5;" |Mutations in:
* ''RPL5''
* ''RPL11''
* ''RPL35A''
* ''RPS7''
* ''RPS10''
* ''RPS17''
* ''RPS19''
* ''RPS24''
* ''RPS26''
| align="left" style="background:#F5F5F5;" |
* Associated with [[myelodysplastic syndrome]]
* Increased risk of [[AML]]
| align="left" style="background:#F5F5F5;" |
* [[Pale skin]]
* Sleepiness
* [[Murmur|Heart murmurs]]
| align="left" style="background:#F5F5F5;" |
* Triphalangeal  thumbs
* [[Short stature]]
* [[Microcephaly]]
* [[Hypertelorism]]
* [[Ptosis]]
* [[Micrognathia]]
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |Anisochromic
| align="center" style="background:#F5F5F5;" |[[Macrocytic anemia|Macrocytic]]
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |↓
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↓
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |NA
|-
! align="center" style="background:#DCDCDC;" |[[Hepato-biliary diseases|Liver disease]]<ref name="pmid23953338">{{cite journal |vauthors=Marks PW |title=Hematologic manifestations of liver disease |journal=Semin. Hematol. |volume=50 |issue=3 |pages=216–21 |date=July 2013 |pmid=23953338 |doi=10.1053/j.seminhematol.2013.06.003 |url=}}</ref>
| align="center" style="background:#F5F5F5;" |−
| align="left" style="background:#F5F5F5;" |
* [[Hepatitis]]
* Binge drinking
* Gall bladder disease
| align="left" style="background:#F5F5F5;" |
* [[Jaundice]]
* [[Abdominal pain]]
* [[Itchy skin]]
| align="left" style="background:#F5F5F5;" |
* [[Ascites]]
* Right upper quadrant pain
* [[Hepatomegaly]]
* [[Edema|Swelling]] in the legs
* [[Ankle swelling]]
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |Anisochromic
| align="center" style="background:#F5F5F5;" |[[Macrocytic anemia|Macrocytic]]
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↓
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="left" style="background:#F5F5F5;" |
* [[Macrocyte|Round macrocytes]]
* [[Macrocyte|Target macrocytes]]
|-
! align="center" style="background:#DCDCDC;" |[[Alcoholism]]<ref name="pmid24588059">{{cite journal |vauthors=Yokoyama A, Yokoyama T, Brooks PJ, Mizukami T, Matsui T, Kimura M, Matsushita S, Higuchi S, Maruyama K |title=Macrocytosis, macrocytic anemia, and genetic polymorphisms of alcohol dehydrogenase-1B and aldehyde dehydrogenase-2 in Japanese alcoholic men |journal=Alcohol. Clin. Exp. Res. |volume=38 |issue=5 |pages=1237–46 |date=May 2014 |pmid=24588059 |doi=10.1111/acer.12372 |url=}}</ref>
| align="center" style="background:#F5F5F5;" |−
| align="left" style="background:#F5F5F5;" |
* History of increased [[Effects of alcohol on the body|alcohol intake]]
* [[Folic acid deficiency]]
| align="left" style="background:#F5F5F5;" |
* [[Memory impairment]]
* [[Nausea]]
* [[Sweating]]
| align="left" style="background:#F5F5F5;" |
* Truncal [[obesity]]
* [[Asterixis]]
* [[Encephalopathy]]
* [[Spider angiomas]]
* [[Hematemesis]]
* [[Gynecomastia]]
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |−
| align="center" style="background:#F5F5F5;" |Anisochromic
| align="center" style="background:#F5F5F5;" |[[Macrocytic anemia|Macrocytic]]
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↓
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="left" style="background:#F5F5F5;" |
* [[Macrocyte|Oval macrocytes]]
* [[Neutrophil|Hypersegmented neutrophils]]
|-
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Disease
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Genetics
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Signs
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hemolysis
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Intrinsic/Extrinsic
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hb concentration
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |MCV
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |RDW
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Reticulocytosis
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Haptoglobin levels
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hepcidin
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Serum iron
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Serum Tfr level
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |IBC
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Ferritin
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Transferrin saturation
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Specific finding on blood smear
|}
===Differentiating myelodysplastic syndrome from other causes of thrombocytopenia===
{|
! colspan="2" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
! colspan="3" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Mechanism
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inherited
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
! colspan="9" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations
! colspan="6" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para−clinical findings
! colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
|-
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms
! colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Signs
|-
! colspan="6" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
|-
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rash
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Jaundice
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |CBC
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
|-
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Decreased platelet production
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet destruction in blood
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet destruction in spleen
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |HB
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC
|-
! rowspan="4" align="center" style="background:#DCDCDC;" + |Bone marrow disorders
! align="center" style="background:#DCDCDC;" + |[[Myelodysplastic syndrome|Myelodysplastic syndromes]]<ref name="NatelsonPyatt2013">{{cite journal|last1=Natelson|first1=Ethan A.|last2=Pyatt|first2=David|title=Acquired Myelodysplasia or Myelodysplastic Syndrome: Clearing the Fog|journal=Advances in Hematology|volume=2013|year=2013|pages=1–11|issn=1687-9104|doi=10.1155/2013/309637}}</ref>
| align="center" style="background:#F5F5F5;" + |
* Unknown
* Mutation
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | ±
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Elderly
| align="center" style="background:#F5F5F5;" + |Exposure to
* [[Chemotherapy]]
* [[Radiation therapy]]
* [[Tobacco smoking|Tobacco smoke]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |[[Petechia|Petechiae]], [[purpura]], diffuse erythematous rash
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
* [[Shortness of breath]]
* [[Fatigue]]
* [[Pallor]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
* Ovalomacrocytosis
* Basophilic stippling
* [[Howell-Jolly body]]
* Dysplastic [[Neutrophil|neutrophils]]
| align="center" style="background:#F5F5F5;" + |
* Impaired [[myeloid]] maturation
* [[Congenital dyserythropoietic anemia|Dyserythropoiesis]]
* Dysgranulopoiesis
* Dysmegakaryocytopoiesis
* Hypercellular [[bone marrow]]
* [[Fibrosis]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |[[Bone marrow examination]] + clinical manifestation
| align="center" style="background:#F5F5F5;" + |
* Might transformed to [[acute leukemia]]
|-
! align="center" style="background:#DCDCDC;" + |[[Aplastic anemia]]<ref name="TownsleyDesmond2013">{{cite journal|last1=Townsley|first1=Danielle M.|last2=Desmond|first2=Ronan|last3=Dunbar|first3=Cynthia E.|last4=Young|first4=Neal S.|title=Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes|journal=International Journal of Hematology|volume=98|issue=1|year=2013|pages=48–55|issn=0925-5710|doi=10.1007/s12185-013-1352-6}}</ref>
| align="center" style="background:#F5F5F5;" + |
* Unknown
* secondary to [[Radiation (medicine)|radiation]], drugs and chemicals, [[pregnancy]], [[Paroxysmal nocturnal hemoglobinuria|PNH]] and viral or [[Autoimmune disease|autoimmune]] causes
 
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | ±
| align="center" style="background:#F5F5F5;" + | ±
| align="center" style="background:#F5F5F5;" + |Biphasic (the young and the elderly)
| align="center" style="background:#F5F5F5;" + |
* Exposure to chemicals
* [[Radiation therapy|Radiation]]
* History of prior drug use
* [[Viral infections|Viral infection]]
* Positive family history of aplastic anemia
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |
* [[Shortness of breath]]
* [[Fatigue]]
* [[Pallor]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
* Large [[Red blood cell|RBCs]]
* Low [[Platelet|platelets]] and [[Granulocyte|granulocytes]]
 
| align="center" style="background:#F5F5F5;" + |
* Hypocellular [[bone marrow]]
* replacement of [[bone marrow]] by [[fat]]
| align="center" style="background:#F5F5F5;" + |
* Elevated PT/PTT
| align="center" style="background:#F5F5F5;" + |[[Bone marrow examination]] +
 
laboratory findings
| align="center" style="background:#F5F5F5;" + |
* [[Fanconi anemia|Fanconi Anemia]]
* [[Dyskeratosis congenita]]
* [[Shwachman-Diamond syndrome|Schwachman-Diamond syndrome]]
* [[Preleukemia]]
|-
! align="center" style="background:#DCDCDC;" + |[[Acute leukemia]]<ref name="OshimaYuji2013">{{cite journal|last1=Oshima|first1=Yasuo|last2=Yuji|first2=Koichiro|last3=Tanimoto|first3=Tetsuya|last4=Hinomura|first4=Yasushi|last5=Tojo|first5=Arinobu|title=Association between Acute Myelogenous Leukemia and Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia|journal=Internal Medicine|volume=52|issue=19|year=2013|pages=2193–2201|issn=0918-2918|doi=10.2169/internalmedicine.52.0324}}</ref><ref name="pmid24088751">{{cite journal |vauthors=Oshima Y, Yuji K, Tanimoto T, Hinomura Y, Tojo A |title=Association between acute myelogenous leukemia and thrombopoietin receptor agonists in patients with immune thrombocytopenia |journal=Intern. Med. |volume=52 |issue=19 |pages=2193–201 |date=2013 |pmid=24088751 |doi= |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
* Immune mediated
* [[Chromosome|Chromosomal]] abnormalities
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | ±
| align="center" style="background:#F5F5F5;" + | ±
| align="center" style="background:#F5F5F5;" + |AML in adults
| align="center" style="background:#F5F5F5;" + |
* Exposure to chemicals
* [[Radiation therapy|Radiation]]
* Pre-existent blood disorders
| align="center" style="background:#F5F5F5;" + | ±
| align="center" style="background:#F5F5F5;" + |[[Petechia|Petechiae]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | ±
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |
* [[Muscle weakness|Weakness]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
* [[Pancytopenia]]
| align="center" style="background:#F5F5F5;" + |
* Blast cells
*
| align="center" style="background:#F5F5F5;" + |
* [[Hemoglobinuria]]
* Elevated PT/PTT
| align="center" style="background:#F5F5F5;" + |Bone marrow examination
| align="center" style="background:#F5F5F5;" + |
* [[Tumor lysis syndrome]]
* [[Infection]]
* [[CNS]] involvement
* [[Disseminated intravascular coagulation|DIC]]
|-
! align="center" style="background:#DCDCDC;" + |[[Paroxysmal nocturnal hemoglobinuria|Paroxysmal nocturnal hemoglobinuria (PNH)]]<ref name="pmid25237200">{{cite journal| author=Brodsky RA| title=Paroxysmal nocturnal hemoglobinuria. | journal=Blood | year= 2014 | volume= 124 | issue= 18 | pages= 2804-11 | pmid=25237200 | doi=10.1182/blood-2014-02-522128 | pmc=4215311 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25237200 }}</ref>
| align="center" style="background:#F5F5F5;" + |
* Deficiency of [[complement]] regulatory proteins
 
* Mutations
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any age
 
(usually younger adults)
| align="center" style="background:#F5F5F5;" + |
* Sudden [[nocturnal]] [[hemoglobinuria]] with partial clearing during the day
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |
* [[Thrombosis]]
* Smooth muscle [[dystonia]]
| align="center" style="background:#F5F5F5;" + |↓/Nl
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓/Nl
| align="center" style="background:#F5F5F5;" + |
* [[Pancytopenia]]
| align="center" style="background:#F5F5F5;" + |
* Cellular [[Bone marrow|marrow]]
* [[Erythroid]] [[hyperplasia]]
* [[dyserythropoiesis]]
 
* Hypocellular marrow in certain stages of the disease
| align="center" style="background:#F5F5F5;" + |
* [[Hemoglobinuria]]
| align="center" style="background:#F5F5F5;" + |[[Flow cytometry]]
 
| align="center" style="background:#F5F5F5;" + |
* [[Chronic renal failure]]
* [[Pulmonary hypertension]]
* [[Aplastic anemia]]
|-
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Decreased platelet production
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet destruction in blood
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet destruction in spleen
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inherited
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rash
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Jaundice
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other signs
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |HB
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
|-
! rowspan="3" align="center" style="background:#DCDCDC;" + |Thrombotic microangiopathy (TMA)
! align="center" style="background:#DCDCDC;" + |[[Thrombotic thrombocytopenic purpura]] ([[Thrombotic thrombocytopenic purpura|TTP]])<ref name="pmid22986360">{{cite journal |vauthors=Noris M, Mescia F, Remuzzi G |title=STEC-HUS, atypical HUS and TTP are all diseases of complement activation |journal=Nat Rev Nephrol |volume=8 |issue=11 |pages=622–33 |date=November 2012 |pmid=22986360 |doi=10.1038/nrneph.2012.195 |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
* Deficiency of, or antibodies to, the metalloprotease [[ADAMTS13]] 
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | ±
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any age
| align="center" style="background:#F5F5F5;" + |
* Neurologic manifestations
* Fatigue due to anemia
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |[[Petechia|Petechiae]]
| align="center" style="background:#F5F5F5;" + |Not common
| align="center" style="background:#F5F5F5;" + |Nl or ↑
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
* [[Neurologic]] findings
* Signs of renal impairment
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |Nl
 
or ↑
| align="center" style="background:#F5F5F5;" + |
* Fragmented [[Red blood cell|RBC]]<nowiki/>s
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + |
* [[Hemoglobinuria]]
| align="center" style="background:#F5F5F5;" + |Laboratory findings
| align="center" style="background:#F5F5F5;" + |
* [[Hemolysis]]
* Microvascular [[thrombosis]]
|-
! align="center" style="background:#DCDCDC;" + |[[Hemolytic-uremic syndrome|Hemolytic uremic syndrome]] ([[Hemolytic-uremic syndrome|HUS]])<ref name="pmid26396094">{{cite journal |vauthors=Conway EM |title=HUS and the case for complement |journal=Blood |volume=126 |issue=18 |pages=2085–90 |date=October 2015 |pmid=26396094 |doi=10.1182/blood-2015-03-569277 |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
* [[Escherichia coli O157:H7]]
* Genetic defects
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | ±
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Children
| align="center" style="background:#F5F5F5;" + |
* Exposure to contaminated water or milk
* Consuming undercooked ground beef
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |[[Petechia|Petechiae]]
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
* [[Tenderness (medicine)|Abdominal tenderness]]
* [[Diarrhea]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |Nl
 
or ↑
| align="center" style="background:#F5F5F5;" + |
* Fragmented [[Red blood cell|RBC]]<nowiki/>s
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + |
* [[Hemoglobinuria]]
| align="center" style="background:#F5F5F5;" + |Laboratory findings
| align="center" style="background:#F5F5F5;" + |
* Acute renal failure [[Hemolysis]]
* Microvascular [[thrombosis]]
|-
! align="center" style="background:#DCDCDC;" + |[[Disseminated intravascular coagulation|DIC]]<ref name="pmid25503977">{{cite journal |vauthors=Schwameis M, Schörgenhofer C, Assinger A, Steiner MM, Jilma B |title=VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP |journal=Thromb. Haemost. |volume=113 |issue=4 |pages=708–18 |date=April 2015 |pmid=25503977 |pmc=4745134 |doi=10.1160/TH14-09-0731 |url=}}</ref><ref name="pmid20008204">{{cite journal |vauthors=Kitchens CS |title=Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC) |journal=Hematology Am Soc Hematol Educ Program |volume= |issue= |pages=240–6 |date=2009 |pmid=20008204 |doi=10.1182/asheducation-2009.1.240 |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
* Overstimulation of the coagulation system
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any age
| align="center" style="background:#F5F5F5;" + |
* History of [[Physical trauma|trauma]], [[sepsis]], [[Cancer|malignancy]], [[vasculitis]] or [[exogenous]] [[Toxin|toxins]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
* [[Neurologic]] findings
* Signs of renal impairment
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓↓
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |
* [[Schistocytes]]
* Helmet cells
| align="center" style="background:#F5F5F5;" + |
* Low [[Platelet|platelets]]
* Low [[Red blood cell|RBCs]]
| align="center" style="background:#F5F5F5;" + |
* [[Hemoglobinuria]]
* Elevated PT/PTT
| align="center" style="background:#F5F5F5;" + |Clinical manifestation + laboratory findings
| align="center" style="background:#F5F5F5;" + |
* [[Hemolysis]]
* [[Microvascular disease|Microangiopathy]]
* Multi-organ dysfunction
|-
! align="center" style="background:#DCDCDC;" |Nutrient deficiencies
! align="center" style="background:#DCDCDC;" |[[Folic Acid|Folate]], [[vitamin B12]], [[copper]] deficiencies<ref name="ClarkeWeston-Smith2010">{{cite journal|last1=Clarke|first1=V.|last2=Weston-Smith|first2=S.|title=Severe folate-deficiency pancytopenia|journal=Case Reports|volume=2010|issue=oct18 2|year=2010|pages=bcr0320102851–bcr0320102851|issn=1757-790X|doi=10.1136/bcr.03.2010.2851}}</ref><ref name="pmid23069991">{{cite journal |vauthors=Blackmer AB, Bailey E |title=Management of copper deficiency in cholestatic infants: review of the literature and a case series |journal=Nutr Clin Pract |volume=28 |issue=1 |pages=75–86 |date=February 2013 |pmid=23069991 |doi=10.1177/0884533612461531 |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
* Decreased platelet production
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any age
| align="center" style="background:#F5F5F5;" + |
* Malnutrition
* Alcohol use
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |
* [[Fatigue]]
* [[Weakness]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |
* Low [[Platelet|platelets]]
* Low [[Red blood cell|RBCs]]
| align="center" style="background:#F5F5F5;" + |
* Low [[Platelet|platelets]]
* Low [[Red blood cell|RBCs]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Laboratory findings
| align="center" style="background:#F5F5F5;" + |
* [[Megaloblastic anemia]]
|-
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Decreased platelet production
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet destruction in blood
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet destruction in spleen
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inherited
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rash
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Jaundice
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other signs
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |HB
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
|-
! rowspan="7" align="center" style="background:#DCDCDC;" + |Congenital platelet disorders<ref name="pmid22726100">{{cite journal| author=Nurden AT, Freson K, Seligsohn U| title=Inherited platelet disorders. | journal=Haemophilia | year= 2012 | volume= 18 Suppl 4 | issue=  | pages= 154-60 | pmid=22726100 | doi=10.1111/j.1365-2516.2012.02856.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22726100  }}</ref><ref name="BalduiniSavoia2012">{{cite journal|last1=Balduini|first1=Carlo L.|last2=Savoia|first2=Anna|title=Genetics of familial forms of thrombocytopenia|journal=Human Genetics|volume=131|issue=12|year=2012|pages=1821–1832|issn=0340-6717|doi=10.1007/s00439-012-1215-x}}</ref><ref name="pmid20011639">{{cite journal| author=D'Andrea G, Chetta M, Margaglione M| title=Inherited platelet disorders: thrombocytopenias and thrombocytopathies. | journal=Blood Transfus | year= 2009 | volume= 7 | issue= 4 | pages= 278-92 | pmid=20011639 | doi=10.2450/2009.0078-08 | pmc=2782805 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20011639  }}</ref>
! align="center" style="background:#DCDCDC;" + |[[MYH9]]-related disorders<ref name="pmid24643058">{{cite journal |vauthors=Zhang S, Zhou X, Liu S, Bai T, Zhang Y, Wang J, Wang S, Zhang X, Wang B |title=MYH9-related disease: description of a large Chinese pedigree and a survey of reported mutations |journal=Acta Haematol. |volume=132 |issue=2 |pages=193–8 |date=2014 |pmid=24643058 |doi=10.1159/000356681 |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
* [[Cytoskeleton|Cytoskeletal]] defects in [[Megakaryocyte|megakaryocytes]]
* Mutation
 
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |Any age, very rare
| align="center" style="background:#F5F5F5;" + |
* Positive family history
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |
* [[Petechia|Petechiae]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |
* [[Sensorineural hearing loss|Hearing loss]]
* Renal impairment
* [[Cataract]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |
* Large [[Platelet|platelets]]
 
* Döhle body-like inclusions in peripheral blood neutrophils
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Genetic study
| align="center" style="background:#F5F5F5;" + |
* [[Dominance relationship|Autosomal dominant]]
|-
! align="center" style="background:#DCDCDC;" + |[[Bernard-Soulier syndrome]]<ref name="pmid21357716">{{cite journal |vauthors=Berndt MC, Andrews RK |title=Bernard-Soulier syndrome |journal=Haematologica |volume=96 |issue=3 |pages=355–9 |date=March 2011 |pmid=21357716 |pmc=3046265 |doi=10.3324/haematol.2010.039883 |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
* Absence of Gp Ib-IX-V 
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |Children, rare
| align="center" style="background:#F5F5F5;" + |
* Positive family history
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + | Nl
| align="center" style="background:#F5F5F5;" + | Nl
| align="center" style="background:#F5F5F5;" + |
* Large [[Platelet|platelets]]
| align="center" style="background:#F5F5F5;" + |
* Large [[Platelet|platelets]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |[[Flow cytometry]]
| align="center" style="background:#F5F5F5;" + |
* [[Autosomal recessive]]
* Increased [[bleeding time]]
|-
! align="center" style="background:#DCDCDC;" + |[[Grey platelet syndrome|Gray platelet syndrome]]<ref name="pmid23427340">{{cite journal |vauthors=Michelson AD |title=Gray platelet syndrome |journal=Blood |volume=121 |issue=2 |pages=250 |date=January 2013 |pmid=23427340 |doi= |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
* Reduction or absence of alpha-granules in [[Blood platelet|blood platelets]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |Rare
| align="center" style="background:#F5F5F5;" + |
* Positive family history
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |
* [[Petechia|Petechiae]]
| align="center" style="background:#F5F5F5;" + | +
Mucocutaneous
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |
* [[Epistaxis]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |
* Large [[Platelet|platelets]] and  lack of granulation
| align="center" style="background:#F5F5F5;" + |
* [[Myelofibrosis]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Genetic study
| align="center" style="background:#F5F5F5;" + |
* [[Autosomal recessive]]
|-
! align="center" style="background:#DCDCDC;" + |[[Wiskott-Aldrich syndrome]]<ref name="pmid29086100">{{cite journal |vauthors=Candotti F |title=Clinical Manifestations and Pathophysiological Mechanisms of the Wiskott-Aldrich Syndrome |journal=J. Clin. Immunol. |volume=38 |issue=1 |pages=13–27 |date=January 2018 |pmid=29086100 |doi=10.1007/s10875-017-0453-z |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
* Mutation in [[GATA1|GATA-1]] 
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |Rare
| align="center" style="background:#F5F5F5;" + |
* Positive family history
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |
* [[Eczema]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |Bloody diarrhea
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |
* Small but low [[Platelet|platelets]]
| align="center" style="background:#F5F5F5;" + |
* Small but low [[Platelet|platelets]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Genetic study
| align="center" style="background:#F5F5F5;" + |
* Recurrent [[Infection|infections]]
 
* [[Autoimmune disease|autoimmune disorders]]
* [[Cancer|Malignancy]]
|-
! align="center" style="background:#DCDCDC;" + |Thrombocytopenia with absent radius (TAR) syndrome<ref name="pmid27981927">{{cite journal |vauthors=Al-Qattan MM |title=The Pathogenesis of Radial Ray Deficiency in Thrombocytopenia-Absent Radius (TAR) Syndrome |journal=J Coll Physicians Surg Pak |volume=26 |issue=11 |pages=912–916 |date=November 2016 |pmid=27981927 |doi=2476 |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
* 1q21.1 [[Deletion (genetics)|deletion]] and [[bone marrow]] failure
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |Children
| align="center" style="background:#F5F5F5;" + |
* Positive family history
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |
* Bilateral [[Radius (bone)|radial]] aplasia
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl or ↑
| align="center" style="background:#F5F5F5;" + |
* Normal size [[Platelet|platelets]]
| align="center" style="background:#F5F5F5;" + |
* Normal or hypercellular [[bone marrow]]
* Decreased, absent, or immature [[Megakaryocyte|megakaryocytes]]
* Small, [[basophilic]], vacuolated [[Megakaryocyte|megakaryocytes]]
* [[Erythroid]] [[hyperplasia]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Evidence of absent radius
+
 
Laboratory findings
| align="center" style="background:#F5F5F5;" + |
* Cow's milk allergy
* Various other anomalies
|-
! align="center" style="background:#DCDCDC;" + |[[Fechtner syndrome]]<ref name="pmid10577925">{{cite journal |vauthors=Toren A, Amariglio N, Rozenfeld-Granot G, Simon AJ, Brok-Simoni F, Pras E, Rechavi G |title=Genetic linkage of autosomal-dominant Alport syndrome with leukocyte inclusions and macrothrombocytopenia (Fechtner syndrome) to chromosome 22q11-13 |journal=Am. J. Hum. Genet. |volume=65 |issue=6 |pages=1711–7 |date=December 1999 |pmid=10577925 |pmc=1288382 |doi=10.1086/302654 |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
* Mutation of chromosome 22q11-13
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |Children
| align="center" style="background:#F5F5F5;" + |
* Positive family history
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |
* [[Bruise|Ecchymoses]] and
[[petechia]]
| align="center" style="background:#F5F5F5;" + | + [[Mucocutaneous zone|Mucocutaneous]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |
* Hearing loss
* Eye abnormalities
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl or ↑
| align="center" style="background:#F5F5F5;" + |
* Large [[Platelet|platelets]]
* Granulocytic inclusions
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + |
* [[Hematuria|Microscopic hematuria]]
* [[Pyuria]]
* [[Hematuria|Red cell]] [[casts]]
* [[Hematuria|Cylindrical]] [[casts]]
* [[Proteinuria]]
| align="center" style="background:#F5F5F5;" + |Clinical manifestation + genetic study
| align="center" style="background:#F5F5F5;" + |
* [[Dominance relationship|Autosomal dominant]] variant of [[Alport syndrome]]
* [[Renal insufficiency|Renal failure]]
* [[Hypoalbuminemia]]
|-
! align="center" style="background:#DCDCDC;" + |[[Von Willebrand disease]]<ref name="pmid24337418">{{cite journal |vauthors=Langer F, Obser T, Oyen F, Spath B, Holstein K, Greinacher A, White JG, Budde U, Bokemeyer C, Schneppenheim R |title=Characterisation of the p.A1461D mutation causing von Willebrand disease type 2B with severe thrombocytopenia, circulating giant platelets, and defective α-granule secretion |journal=Thromb. Haemost. |volume=111 |issue=4 |pages=777–9 |date=April 2014 |pmid=24337418 |doi=10.1160/TH13-06-0462 |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
* [[Von Willebrand factor|VWF]] deficiency/dysfunction
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Rarely
| align="center" style="background:#F5F5F5;" + |More common with [[ABO blood group system|O blood type]]
| align="center" style="background:#F5F5F5;" + |
* Positive family history
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |Nl/ ↓
| align="center" style="background:#F5F5F5;" + |Nl/↓
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |
* Large [[Platelet|platelets]]
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + |
* [[Hematuria]]
| align="center" style="background:#F5F5F5;" + |Laboratory findings
| align="center" style="background:#F5F5F5;" + |
* Lifelong bleeding disorder
|-
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Decreased platelet production
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet destruction in blood
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet destruction in spleen
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inherited
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rash
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Jaundice
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other signs
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |HB
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |[[Idiopathic thrombocytopenic purpura|ITP]]<ref name="ZuffereyKapur2017">{{cite journal|last1=Zufferey|first1=Anne|last2=Kapur|first2=Rick|last3=Semple|first3=John|title=Pathogenesis and Therapeutic Mechanisms in  Immune Thrombocytopenia (ITP)|journal=Journal of Clinical Medicine|volume=6|issue=2|year=2017|pages=16|issn=2077-0383|doi=10.3390/jcm6020016}}</ref>
| align="center" style="background:#F5F5F5;" + |
* Immune-mediated [[platelet]] destruction
* Inhibition of [[platelet]] release from the [[megakaryocyte]] 
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any age
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |
* [[Bruise|Ecchymoses]] and
[[petechia]]
| align="center" style="background:#F5F5F5;" + | + [[Mucocutaneous zone|Mucocutaneous]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |↓↓↓
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |
* Large [[Platelet|platelets]], otherwise normal
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Diagnosis of exclusion
| align="center" style="background:#F5F5F5;" + |
* Spontaneous remission 
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |[[Systemic lupus erythematosus]]<ref name="pmid27777394">{{cite journal |vauthors=Abu-Hishmeh M, Sattar A, Zarlasht F, Ramadan M, Abdel-Rahman A, Hinson S, Hwang C |title=Systemic Lupus Erythematosus Presenting as Refractory Thrombotic Thrombocytopenic Purpura: A Diagnostic and Management Challenge. A Case Report and Concise Review of the Literature |journal=Am J Case Rep |volume=17 |issue= |pages=782–787 |date=October 2016 |pmid=27777394 |pmc=5083062 |doi= |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
* Immune-mediated [[platelet]] destruction
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Young women, more prevalent in Africans and Asians
| align="center" style="background:#F5F5F5;" + |
* Medication use
* History of [[Weight change|weight changes]]
* Other [[Rheumatologic disease|rheumatologic]] and [[autoimmune diseases]]
* [[Family history]] of [[Rheumatologic disease|rheumatologic diseases]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |[[Malar rash]], generalized [[maculopapular rash]], discoid rash
| align="center" style="background:#F5F5F5;" + | +
 
[[Hemoptysis]]
| align="center" style="background:#F5F5F5;" + |Nl or ↑
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
* Mucosal ulcers
* [[Lymphadenopathy]]
* [[Rales|Crackles]]
* Chest [[tenderness]]
* [[Heart murmur|Murmur]]
* [[Hepatomegaly]]
* [[Cognitive impairment]]


==Differenting Myeloproliferative disease from other Diseases==
| align="center" style="background:#F5F5F5;" + |↓
Differential Diagnosis (for dysplasia)
| align="center" style="background:#F5F5F5;" + |↓
* Arsenic, Lead, Benzene, Xylene, petroleum, Agent Orange (Vietnam Veterans).
| align="center" style="background:#F5F5F5;" + |↓
* Congenital Dyserythropoietic anemia
| align="center" style="background:#F5F5F5;" + |
* HIV
* [[Pancytopenia]]
* Vitamin B12 / folate
| align="center" style="background:#F5F5F5;" + |
* Parvovirus
* [[Pancytopenia]]
* Alcohol abuse
| align="center" style="background:#F5F5F5;" + |
* Prior chemotherapy (eg. melphalan, mustard, chlorambucil, busulfan, cyclophosphamide).
** [[Hematuria]]
* Radiation (with or without chemotherapy).
** [[Pyuria]]
** [[Proteinuria]]
** Cellular casts
** Elevated PT/PTT
| align="center" style="background:#F5F5F5;" + |Clinical manifestation + serology
| align="center" style="background:#F5F5F5;" + |
* [[Thrombotic thrombocytopenic purpura|TTP]]
* Multiorgan dysfunction
* [[Infections]]
* [[Atherosclerosis]]
* [[Malignancies]]
* Poor prognosis with lupus nephritis
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |[[Antiphospholipid syndrome]]<ref name="Artim-EsenDiz-Küçükkaya2015">{{cite journal|last1=Artim-Esen|first1=Bahar|last2=Diz-Küçükkaya|first2=Reyhan|last3=İnanç|first3=Murat|title=The Significance and Management of Thrombocytopenia in Antiphospholipid Syndrome|journal=Current Rheumatology Reports|volume=17|issue=3|year=2015|issn=1523-3774|doi=10.1007/s11926-014-0494-8}}</ref>
| align="center" style="background:#F5F5F5;" + |
* Autoantibody-mediated syndrome
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Middle aged women, more in African American and Hispanic population
| align="center" style="background:#F5F5F5;" + |
* Abortion
* Other [[Rheumatologic disease|rheumatologic]] and [[autoimmune diseases]]
* [[Family history]] of [[Rheumatologic disease|rheumatologic diseases]]
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |
* [[Deep vein thrombosis|DVT]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
* Reduced [[Platelet|platelets]] and [[White blood cells|WBC]]
| align="center" style="background:#F5F5F5;" + |
* Reduced [[Platelet|platelets]] and [[White blood cells|WBC]]
| align="center" style="background:#F5F5F5;" + |
* [[Hematuria]]
* Elevated PTT
| align="center" style="background:#F5F5F5;" + |Clinical manifestation + repeated positive tests of aPL
| align="center" style="background:#F5F5F5;" + |
* Recurrent [[thrombosis]]
* [[Stroke]]
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |[[Felty's syndrome]]<ref name="ChavalitdhamrongMolovic-Kokovic2009">{{cite journal|last1=Chavalitdhamrong|first1=Disaya|last2=Molovic-Kokovic|first2=Ana|last3=Iliev|first3=Andrey|title=Felty's Syndrome as an initial presentation of Rheumatoid Arthritis: a case report|journal=Cases Journal|volume=2|issue=1|year=2009|pages=206|issn=1757-1626|doi=10.1186/1757-1626-2-206}}</ref>
| align="center" style="background:#F5F5F5;" + |
* Autoantibody-mediated syndrome
* [[Splenomegaly]]
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | ±
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Rare, young women
| align="center" style="background:#F5F5F5;" + |
* [[Arthritis]]
* Family history of [[Rheumatoid arthritis|RA]]
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |
* [[Necrosis|Necrotizing]] skin lesions
* [[Rheumatoid nodule]]
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |
* Lymphadenopathy
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
* Reduced [[Platelet|platelets]] and [[White blood cells|WBC]]
| align="center" style="background:#F5F5F5;" + |
* Reduced [[Platelet|platelets]] and [[White blood cells|WBC]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Clinical manifestation
| align="center" style="background:#F5F5F5;" + |
* [[Rheumatoid arthritis]]
* Positive [[Rheumatoid factor|RF]] and anti-citrullinated peptide antibodies
* [[Episcleritis]]
* Pleuropericarditis
|-
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Decreased platelet production
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet destruction in blood
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet destruction in spleen
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inherited
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rash
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Jaundice
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other signs
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |HB
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
|-
! rowspan="3" align="center" style="background:#DCDCDC;" + |[[Infection|Bacterial infections]]
! align="center" style="background:#DCDCDC;" + |[[Sepsis]]<ref name="WuRen2014">{{cite journal|last1=Wu|first1=Qin|last2=Ren|first2=Jianan|last3=Wu|first3=Xiuwen|last4=Wang|first4=Gefei|last5=Gu|first5=Guosheng|last6=Liu|first6=Song|last7=Wu|first7=Yin|last8=Hu|first8=Dong|last9=Zhao|first9=Yunzhao|last10=Li|first10=Jieshou|title=Recombinant human thrombopoietin improves platelet counts and reduces platelet transfusion possibility among patients with severe sepsis and thrombocytopenia: A prospective study|journal=Journal of Critical Care|volume=29|issue=3|year=2014|pages=362–366|issn=08839441|doi=10.1016/j.jcrc.2013.11.023}}</ref>
| align="center" style="background:#F5F5F5;" + |
* Direct [[bone marrow suppression]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any
| align="center" style="background:#F5F5F5;" + |
* [[Infection|Bacterial infection]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
* [[Petechiae]]
* [[Purpura]]
* [[Erythema]]
* [[Ulcer|Ulceration]]
| align="center" style="background:#F5F5F5;" + | ±
| align="center" style="background:#F5F5F5;" + |Nl to ↓
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | ±
| align="center" style="background:#F5F5F5;" + |
* [[Malaise]]
* [[Lymphadenopathy]]
| align="center" style="background:#F5F5F5;" + |↓/↑
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |↑↑
| align="center" style="background:#F5F5F5;" + |
* Reduced [[Platelet|platelets]]
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + |
* Elevated PT/PTT
| align="center" style="background:#F5F5F5;" + |Clinical manifestation + culture
| align="center" style="background:#F5F5F5;" + |
* Associated with ↑ mortality
|-
! align="center" style="background:#DCDCDC;" + |[[Helicobacter pylori]]<ref name="pmid24574745">{{cite journal |vauthors=Kuwana M |title=Helicobacter pylori-associated immune thrombocytopenia: clinical features and pathogenic mechanisms |journal=World J. Gastroenterol. |volume=20 |issue=3 |pages=714–23 |date=January 2014 |pmid=24574745 |pmc=3921481 |doi=10.3748/wjg.v20.i3.714 |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
* Immune thrombocytopenia
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |
* Epigastric tenderness
* [[Heartburn]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |
* Reduced [[Platelet|platelets]]
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Clinical manifestation + culture
| align="center" style="background:#F5F5F5;" + |
* [[Gastroesophageal reflux disease|GERD]]
|-
! align="center" style="background:#DCDCDC;" + |[[Tick-borne disease|Tick-borne infection]]<ref name="pmid24837566">{{cite journal |vauthors=Liu Q, He B, Huang SY, Wei F, Zhu XQ |title=Severe fever with thrombocytopenia syndrome, an emerging tick-borne zoonosis |journal=Lancet Infect Dis |volume=14 |issue=8 |pages=763–772 |date=August 2014 |pmid=24837566 |doi=10.1016/S1473-3099(14)70718-2 |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
* Immune thrombocytopenia
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Endemic area like China, Japan, and Korea
| align="center" style="background:#F5F5F5;" + |
* Being bitten by a tick
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
* [[Petechiae]]
* [[Purpura]]
* [[Erythema]]
* [[Ulcer|Ulceration]]
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + |Nl to ↓
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + |
* [[Encephalitis]]
* [[Viral hemorrhagic fever|Hemorrhagic fever]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
* Reduced [[Platelet|platelets]]
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + |
* [[Proteinuria]]
| align="center" style="background:#F5F5F5;" + |[[Polymerase chain reaction|PCR]]
| align="center" style="background:#F5F5F5;" + |
* Elevated [[Alanine transaminase|ALT]] and [[Aspartate transaminase|AST]]
* [[Multiple organ dysfunction syndrome|Multiple organ failure]]
* [[Lymphadenopathy]]
|-
! rowspan="2" align="center" style="background:#DCDCDC;" + |[[Virus|Viral infections]]
! align="center" style="background:#DCDCDC;" + |[[Human Immunodeficiency Virus (HIV)|HIV]]<ref name="pmid26098601">{{cite journal |vauthors=Borges ÁH, Lundgren JD, Mocroft A |title=Thrombocytopenia and cancer risk during HIV infection |journal=AIDS |volume=29 |issue=11 |pages=1425–7 |date=July 2015 |pmid=26098601 |doi=10.1097/QAD.0000000000000744 |url=}}</ref>
| align="Left" style="background:#F5F5F5;" + |
* Immune thrombocytopenia
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any
| align="center" style="background:#F5F5F5;" + |
* High risk behaviors
* Close contact
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
* [[Skin lesions]]
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + |Nl to ↓
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + |
* [[Lymphadenopathy]]
* [[Muscle weakness]]
* [[Joint swelling]]
* Focal neurological deficits
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
* [[Pancytopenia]]
| align="center" style="background:#F5F5F5;" + |
* [[Pancytopenia]]
| align="center" style="background:#F5F5F5;" + |
* [[Proteinuria]]
* Elevated PT/PTT
| align="center" style="background:#F5F5F5;" + |Isolation of [[Human Immunodeficiency Virus (HIV)|HIV]]
| align="center" style="background:#F5F5F5;" + |
* [[Cancer|Malignancy]]
* Severe [[immunodeficiency]]
|-
! align="center" style="background:#DCDCDC;" + |Other viruses such as [[rubella]], [[mumps]], [[varicella]], [[parvovirus]], [[hepatitis C]], & [[Epstein Barr virus|Epstein-Barr virus]]<ref name="pmid25518779">{{cite journal |vauthors=Saeed M, Dabbagh O, Al-Muhaizae M, Dhalaan H, Chedrawi A |title=Acute disseminated encephalomyelitis and thrombocytopenia following Epstein-Barr virus infection |journal=J Coll Physicians Surg Pak |volume=24 Suppl 3 |issue= |pages=S216–8 |date=November 2014 |pmid=25518779 |doi=11.2014/JCPSP.S216S218 |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
* Immune thrombocytopenia
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any
| align="center" style="background:#F5F5F5;" + |
* High risk behaviors
* Close contact
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
* [[Petechiae]]
* [[Purpura]]
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + |
* [[Lymphadenopathy]]
* [[Muscle weakness]]
* [[Joint swelling]]
* Focal neurological deficits
* Depends on etiology
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
* [[Pancytopenia]]
| align="center" style="background:#F5F5F5;" + |
* [[Pancytopenia]]
| align="center" style="background:#F5F5F5;" + |
* [[Hematuria]]
| align="center" style="background:#F5F5F5;" + |Clinical manifestation + lab tests
| align="center" style="background:#F5F5F5;" + |
* Depends on etiology
* [[Encephalomyelitis]]
|-
! rowspan="2" align="center" style="background:#DCDCDC;" + |[[Parasitism|Parasitic infections]]
! align="center" style="background:#DCDCDC;" + |[[Malaria]]<ref name="pmid25131143">{{cite journal |vauthors=Rodriguez-Morales AJ, Giselle-Badillo A, Manrique-Castaño S, Yepes MC |title=Anemia and thrombocytopenia in Plasmodium vivax malaria is not unusual in patients from endemic and non-endemic settings |journal=Travel Med Infect Dis |volume=12 |issue=5 |pages=549–50 |date=2014 |pmid=25131143 |doi=10.1016/j.tmaid.2014.07.006 |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
* Unknown
* Immune thrombocytopenia
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Endemic area
| align="center" style="background:#F5F5F5;" + |
* Being bitten by a mosquito
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + |Nl to ↓
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + |
* [[Headache]]
* [[Weakness]]
* [[Night sweats]]
* [[Joint pain]]
* [[Muscle pain]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
* [[Pancytopenia]]
| align="center" style="background:#F5F5F5;" + |
* [[Pancytopenia]]
| align="center" style="background:#F5F5F5;" + |
* [[Hematuria]]
| align="center" style="background:#F5F5F5;" + |Clinical manifestation + microscopic examination of blood smear
| align="center" style="background:#F5F5F5;" + |
* Life-threatening disease
* [[Multiple organ dysfunction syndrome|Multiple organ failure]]
|-
! align="center" style="background:#DCDCDC;" + |[[Babesiosis]]<ref name="pmid24783256">{{cite journal |vauthors=Nackos E, DeSancho M |title=Anemia and thrombocytopenia: diagnosis from the blood smear |journal=Blood |volume=123 |issue=12 |pages=1783 |date=March 2014 |pmid=24783256 |doi= |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
* Unknown
* Immune thrombocytopenia
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Rare
| align="center" style="background:#F5F5F5;" + |
* Being bitten by a tick
* [[Immunodeficiency]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + |Nl to ↓
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + |
* [[Fatigue]]
* [[Rigor|Chills]]
* [[Perspiration|Sweats]]
* [[Headache]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
* [[Pancytopenia]]
| align="center" style="background:#F5F5F5;" + |
* [[Pancytopenia]]
| align="center" style="background:#F5F5F5;" + |
* [[Hematuria]]
| align="center" style="background:#F5F5F5;" + |Clinical manifestation + microscopic examination of blood smear
| align="center" style="background:#F5F5F5;" + |
* Severe hemolytic anemia
* [[Disseminated intravascular coagulation|DIC]]
* [[Multiple organ dysfunction syndrome|Multiple organ failure]]
|-
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Decreased platelet production
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet destruction in blood
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet destruction in spleen
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inherited
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rash
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Jaundice
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other signs
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |HB
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
|-
! align="center" style="background:#DCDCDC;" + |[[Antibiotic|Antibiotics]]/
[[Anticonvulsant|Antiepileptic]]<ref name="pmid17666285">{{cite journal |vauthors=Visentin GP, Liu CY |title=Drug-induced thrombocytopenia |journal=Hematol. Oncol. Clin. North Am. |volume=21 |issue=4 |pages=685–96, vi |date=August 2007 |pmid=17666285 |pmc=1993236 |doi=10.1016/j.hoc.2007.06.005 |url=}}</ref>
! align="left" style="background:#DCDCDC;" + |
* [[Quinine]]
* [[Sulfonamide (medicine)|Sulfonamides]]
* [[Carbamazepine]]
* [[Phenytoin]]
| align="center" style="background:#F5F5F5;" + |
* Occurrence of drug-dependent, platelet-reactive [[antibodies]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any
| align="center" style="background:#F5F5F5;" + |
* Drug ingestion or injection
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |
* [[Bruise|Ecchymoses]]
* [[Petechia]]
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |↓↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |
* Reduced [[Platelet|platelets]]
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Clinical manifestation + exclusion of the other causes
| align="center" style="background:#F5F5F5;" + |NA
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |[[Heparin-induced thrombocytopenia]]<ref name="Lovecchio2014">{{cite journal|last1=Lovecchio|first1=F.|title=Heparin-induced thrombocytopenia|journal=Clinical Toxicology|volume=52|issue=6|year=2014|pages=579–583|issn=1556-3650|doi=10.3109/15563650.2014.917181}}</ref>
| align="center" style="background:#F5F5F5;" + |
* Anti-heparin/PF4 antibody
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any
| align="center" style="background:#F5F5F5;" + |
* Heparin injection
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |
* Necrotic skin lesions
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |
* Reduced [[Platelet|platelets]]
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |[[Enzyme linked immunosorbent assay (ELISA)|ELISA]]
| align="center" style="background:#F5F5F5;" + |
* Early or delayed-onset
* [[Thrombosis]]
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |[[Chemotherapy|Cytotoxic chemotherapy]]<ref name="ParameswaranLunning2014">{{cite journal|last1=Parameswaran|first1=R.|last2=Lunning|first2=M.|last3=Mantha|first3=S.|last4=Devlin|first4=S.|last5=Hamilton|first5=A.|last6=Schwartz|first6=G.|last7=Soff|first7=G.|title=Romiplostim for management of chemotherapy-induced thrombocytopenia|journal=Supportive Care in Cancer|volume=22|issue=5|year=2014|pages=1217–1222|issn=0941-4355|doi=10.1007/s00520-013-2074-2}}</ref>
| align="center" style="background:#F5F5F5;" + |
* [[Bone marrow suppression]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Patients with [[Cancer|malignancy]]
| align="center" style="background:#F5F5F5;" + |
* Drug ingestion or injection
* [[Cancer]]
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |
* [[Bruise|Ecchymoses]]
* Petechia
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
* Reduced [[Platelet|platelets]]
| align="center" style="background:#F5F5F5;" + |
* Megakaryocytic hypoplasia or aplasia
| align="center" style="background:#F5F5F5;" + |
* [[Hematuria case study one|Hematuria]]
* Elevated PT/PTT
| align="center" style="background:#F5F5F5;" + |Clinical manifestation + exclusion of the other causes
| align="center" style="background:#F5F5F5;" + |
* [[Thrombosis]]
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |[[Radiation therapy]]<ref name="pmid23233625">{{cite journal |vauthors=Bercovitz RS, Josephson CD |title=Thrombocytopenia and bleeding in pediatric oncology patients |journal=Hematology Am Soc Hematol Educ Program |volume=2012 |issue= |pages=499–505 |date=2012 |pmid=23233625 |doi=10.1182/asheducation-2012.1.499 |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
* Predictable, dose-dependent [[Bone marrow suppression|myelosuppression]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Patients with [[Cancer|malignancy]]
| align="center" style="background:#F5F5F5;" + |
* [[Radiation therapy|Radiation]]
* [[Cancer]]
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |
* [[Purpura]]
* [[Petechia|Petechiae]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |
* Reduced [[Platelet|platelets]]
| align="center" style="background:#F5F5F5;" + |
* Megakaryocytic hypoplasia or aplasia
| align="center" style="background:#F5F5F5;" + |
* [[Hematuria case study one|Hematuria]]
* Elevated PT/PTT
| align="center" style="background:#F5F5F5;" + |Clinical manifestation + exclusion of the other causes
| align="center" style="background:#F5F5F5;" + |
* [[Thrombosis]]
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |[[Chronic liver disease]]<ref name="LoffredoVioli20182">{{cite journal|last1=Loffredo|first1=Lorenzo|last2=Violi|first2=Francesco|title=Thrombopoietin receptor agonists and risk of portal vein thrombosis in patients with liver disease and thrombocytopenia: A meta-analysis|journal=Digestive and Liver Disease|year=2018|issn=15908658|doi=10.1016/j.dld.2018.06.005}}</ref>
| align="center" style="background:#F5F5F5;" + |
* [[Bone marrow suppression]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any
| align="center" style="background:#F5F5F5;" + |
* [[Cirrhosis]]
* [[Alcoholism|Alcohol use]]
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |
* [[Purpura]]
* [[Petechia|Petechiae]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |
* Reduced [[Platelet|platelets]]
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + |
* [[Hematuria case study one|Hematuria]]
* Elevated PT/PTT
| align="center" style="background:#F5F5F5;" + |[[Biopsy]]
| align="center" style="background:#F5F5F5;" + |
* [[Portal vein thrombosis]]
* [[Hepatorenal syndrome]]
* Variceal hemorrhage
* Hepatic [[hydrothorax]]
* [[Spontaneous bacterial peritonitis]]
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |[[Portal hypertension]]<ref name="pmid17729421">{{cite journal |vauthors=Jia YP, Lu Q, Gong S, Ma BY, Wen XR, Peng YL, Lin L, Chen HY, Qiu L, Luo Y |title=Postoperative complications in patients with portal vein thrombosis after liver transplantation: evaluation with Doppler ultrasonography |journal=World J. Gastroenterol. |volume=13 |issue=34 |pages=4636–40 |date=September 2007 |pmid=17729421 |pmc=4611842 |doi= |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
* [[Bone marrow suppression]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any
| align="center" style="background:#F5F5F5;" + |
* [[Cirrhosis]]
* [[Alcoholism|Alcohol use]]
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |
* [[Purpura]]
* [[Petechia|Petechiae]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |
* Reduced [[Platelet|platelets]]
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + |
* Elevated PT/PTT
| align="center" style="background:#F5F5F5;" + |Clinical manifestation
| align="center" style="background:#F5F5F5;" + |
* [[Portal vein thrombosis]]
* [[Ascites]]
|-
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Decreased platelet production
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet destruction in blood
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet destruction in spleen
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inherited
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rash
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Jaundice
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other signs
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |HB
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |Giant capillary hemangioma ([[Kasabach-Merritt syndrome]])<ref>Lewis D, Vaidya R. Kasabach Merritt Syndrome. [Updated 2018 Jul 27]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-. Available from: https://www-ncbi-nlm-nih-gov.ezp-prod1.hul.harvard.edu/books/NBK519053/</ref><ref name="VinodJohny2017">{{cite journal|last1=Vinod|first1=Kolar Vishwanath|last2=Johny|first2=Joseph|last3=Vadivelan|first3=Mehalingam|last4=Hamide|first4=Abdoul|title=Kasabach-Merritt Syndrome in an adult|journal=Turkish Journal of Hematology|year=2017|issn=13007777|doi=10.4274/tjh.2017.0429}}</ref>
| align="center" style="background:#F5F5F5;" + |
* [[Platelet]] destruction
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |Infants
| align="center" style="background:#F5F5F5;" + |
* Rare but serious infantile [[coagulopathy]]
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |
* Multiple purple [[hemangioma]]
| align="center" style="background:#F5F5F5;" + | Intralesional [[bleeding]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |Visceral hemangiomas
| align="center" style="background:#F5F5F5;" + |↓↓
| align="center" style="background:#F5F5F5;" + |↓↓
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Normocytic normochromic [[erythrocytes]] and markedly reduced [[platelets]]
| align="center" style="background:#F5F5F5;" + |Normal [[erythropoiesis]], myelopoiesis, and megakaryocytic hyperplasia
| align="center" style="background:#F5F5F5;" + |
* [[Hematuria case study one|Hematuria]]
* Elevated PT/PTT
| align="center" style="background:#F5F5F5;" + |[[Biopsy]]
| align="center" style="background:#F5F5F5;" + |
* Kaposiform hemangioendothelioma
* Tufted angioma
*  
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |[[Cardiopulmonary bypass]]<ref name="JiKim2015">{{cite journal|last1=Ji|first1=Sung-Mi|last2=Kim|first2=Sung-Hoon|last3=Nam|first3=Jae-Sik|last4=Yun|first4=Hye-Joo|last5=Choi|first5=Jeong-Hyun|last6=Lee|first6=Eun-Ho|last7=Choi|first7=In-Cheol|title=Predictive value of rotational thromboelastometry during cardiopulmonary bypass for thrombocytopenia and hypofibrinogenemia after weaning of cardiopulmonary bypass|journal=Korean Journal of Anesthesiology|volume=68|issue=3|year=2015|pages=241|issn=2005-6419|doi=10.4097/kjae.2015.68.3.241}}</ref>
| align="center" style="background:#F5F5F5;" + |
* [[Platelet]] destruction
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Elderly
| align="center" style="background:#F5F5F5;" + |
* [[Coronary heart disease|Coronary artery disease]]
| align="center" style="background:#F5F5F5;" + |−
| align="center" style="background:#F5F5F5;" + |
* [[Purpura]]
* [[Petechia|Petechiae]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Nl or ↑
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Normocytic normochromic [[erythrocytes]] and markedly reduced [[platelets]]
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + |
* [[Hematuria case study one|Hematuria]]
* Elevated PT/PTT
| align="center" style="background:#F5F5F5;" + |Clinical manifestation
| align="center" style="background:#F5F5F5;" + |
* [[Coagulopathy]]
* [[Hypofibrinogenemia]]
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |[[Alcohol]]<ref name="pmid15100613">{{cite journal |vauthors=Latvala J, Parkkila S, Niemelä O |title=Excess alcohol consumption is common in patients with cytopenia: studies in blood and bone marrow cells |journal=Alcohol. Clin. Exp. Res. |volume=28 |issue=4 |pages=619–24 |date=April 2004 |pmid=15100613 |doi= |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
* [[Platelet]] production suppression
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any
| align="center" style="background:#F5F5F5;" + |
* History of [[Alcoholism|alcohol use]]
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
* [[Hepatomegaly]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |[[Cytopenia]], [[macrocytosis]]
| align="center" style="background:#F5F5F5;" + |[[Cytopenia]], [[macrocytosis]]
| align="center" style="background:#F5F5F5;" + |
* Elevated PT/PTT
| align="center" style="background:#F5F5F5;" + |Clinical manifestation
| align="center" style="background:#F5F5F5;" + |
* [[Chronic liver disease]]
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |[[Post-transfusion purpura]]<ref name="McCraeHerman1996">{{cite journal|last1=McCrae|first1=Keith R.|last2=Herman|first2=Jay H.|title=Posttransfusion purpura: Two unusual cases and a literature review|journal=American Journal of Hematology|volume=52|issue=3|year=1996|pages=205–211|issn=03618609|doi=10.1002/(SICI)1096-8652(199607)52:3<205::AID-AJH13>3.0.CO;2-E}}</ref><ref name="PavenskiWebert2008">{{cite journal|last1=Pavenski|first1=Katerina|last2=Webert|first2=Kathryn E.|last3=Goldman|first3=Mindy|title=Consequences of transfusion of platelet antibody: a case report and literature review|journal=Transfusion|volume=48|issue=9|year=2008|pages=1981–1989|issn=00411132|doi=10.1111/j.1537-2995.2008.01796.x}}</ref>
| align="center" style="background:#F5F5F5;" + |
* [[Platelet]] destruction by anti-platelet [[antibodies]]
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Women
| align="center" style="background:#F5F5F5;" + |
* History of [[blood transfusion]] or pregnancy
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |
* [[Purpura]]
* [[Petechia|Petechiae]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |↓↓↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Positive circulating alloantibody to a common [[platelet]] antigen
| align="center" style="background:#F5F5F5;" + |
* Severe but rare reaction
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |Gestational thrombocytopenia<ref name="ReesePeck2018">{{cite journal|last1=Reese|first1=Jessica A.|last2=Peck|first2=Jennifer D.|last3=Deschamps|first3=David R.|last4=McIntosh|first4=Jennifer J.|last5=Knudtson|first5=Eric J.|last6=Terrell|first6=Deirdra R.|last7=Vesely|first7=Sara K.|last8=George|first8=James N.|title=Platelet Counts during Pregnancy|journal=New England Journal of Medicine|volume=379|issue=1|year=2018|pages=32–43|issn=0028-4793|doi=10.1056/NEJMoa1802897}}</ref>
| align="center" style="background:#F5F5F5;" + |
* Might be physiologic adaptation of pregnancy
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Pregnant women
| align="center" style="background:#F5F5F5;" + |
* Positive history of mild thrombocytopenia
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Diagnosis of exclusion
| align="center" style="background:#F5F5F5;" + |
* Self-limited condition
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |[[HELLP syndrome]]<ref name="Barnhart2015">{{cite journal|last1=Barnhart|first1=Lynette|title=HELLP Syndrome and the Effects on the Neonate|journal=Neonatal Network|volume=34|issue=5|year=2015|pages=269–273|issn=07300832|doi=10.1891/0730-0832.34.5.269}}</ref><ref name="HaramSvendsen2009">{{cite journal|last1=Haram|first1=Kjell|last2=Svendsen|first2=Einar|last3=Abildgaard|first3=Ulrich|title=The HELLP syndrome: Clinical issues and management. A Review|journal=BMC Pregnancy and Childbirth|volume=9|issue=1|year=2009|issn=1471-2393|doi=10.1186/1471-2393-9-8}}</ref>
| align="center" style="background:#F5F5F5;" + |
* Unknown
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Pregnant > 25 years
| align="center" style="background:#F5F5F5;" + |
* History of [[Pre-eclampsia|preeclampsia]]
*  
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
* [[Tenderness (medicine)|Abdominal tenderness]]
* [[Ascites]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |[[Red blood cell|Schistocytes]]
| align="center" style="background:#F5F5F5;" + |NA
| align="center" style="background:#F5F5F5;" + |[[Proteinuria]]
| align="center" style="background:#F5F5F5;" + |Lab abnormalities
| align="center" style="background:#F5F5F5;" + |
* Elevated [[Liver function tests|liver enzymes]] and [[bilirubin]]
* Multiorgan dysfunction
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Idiopathic cyclic thrombocytopenia<ref name="Go2005">{{cite journal|last1=Go|first1=Ronald S.|title=Idiopathic cyclic thrombocytopenia|journal=Blood Reviews|volume=19|issue=1|year=2005|pages=53–59|issn=0268960X|doi=10.1016/j.blre.2004.05.001}}</ref>
| align="left" style="background:#F5F5F5;" + |
* Unknown
* Might be [[Autoimmunity|autoimmune]] platelet destruction
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Females with the median age of onset 35 years
| align="left" style="background:#F5F5F5;" + |
* Misdiagnosed as [[Idiopathic thrombocytopenic purpura|ITP]] with uniformly poor responses
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |
* [[Purpura]]
* [[Petechia|Petechiae]]
| align="center" style="background:#F5F5F5;" + |Minor mucocutaneous [[bleeding]]
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + | −
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Reduced [[Platelet|platelets]] and [[Megakaryocyte|megakaryocytes]]
| align="center" style="background:#F5F5F5;" + |[[Myelofibrosis|Megakaryocytic]] hypoplasia or aplasia
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Diagnosis of exclusion
| align="left" style="background:#F5F5F5;" + |
* Rebound [[thrombocytosis]]
* [[Myeloproliferative neoplasm|Myeloproliferative diseases]]
* [[Myelodysplastic syndrome]]
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Pseudothrombocytopenia<ref name="TanStalling2016">{{cite journal|last1=Tan|first1=Geok Chin|last2=Stalling|first2=Melissa|last3=Dennis|first3=Gretchen|last4=Nunez|first4=Maria|last5=Kahwash|first5=Samir B.|title=Pseudothrombocytopenia due to Platelet Clumping: A Case Report and Brief Review of the Literature|journal=Case Reports in Hematology|volume=2016|year=2016|pages=1–4|issn=2090-6560|doi=10.1155/2016/3036476}}</ref>
| align="center" style="background:#F5F5F5;" |
* [[Platelet]] clumping due to [[EDTA]]
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |Rare
| align="center" style="background:#F5F5F5;" | Collected sample in [[EDTA]] anticoagulant
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" |↓
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" | Low [[platelet]] count and [[platelet]] clumps
| align="center" style="background:#F5F5F5;" | Low [[platelet]] count and [[platelet]] clumps
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Repeat collecting sample in a [[heparin]] tube
| align="center" style="background:#F5F5F5;" | Nl
|-
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Decreased platelet production
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet destruction in blood
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet destruction in spleen
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inherited
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rash
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Jaundice
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other signs
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Plt
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |HB
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bone marrow exam
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings
|}


==References==
==References==
{{reflist|2}}
{{reflist|2}}
 
[[Category:Up-To-Date]]
[[Category:Disease]]
[[Category:Oncology]]
[[Category:Types of cancer]]
[[Category:Medicine]]
[[Category:Hematology]]
[[Category:Neurology]]
 
[[Category:Neurosurgery]]
{{WikiDoc Help Menu}}
[[Category:Differential diagnosis]]
{{WikiDoc Sources}}

Latest revision as of 20:49, 28 February 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Hannan Javed, M.D.[2] Zahir Ali Shaikh, MD[3] Nawal Muazam M.D.[4] Amandeep Singh M.D.[5]

Overview

Myelodysplastic syndrome must be differentiated from other diseases that cause anemia, neutropenia, and thrombocytopenia, such as: aplastic anemia, fanconi anemia, pure red cell aplasia, Shwachman-Diamond syndrome, paroxysmal nocturnal hemoglobinuria, parovirus B19 infection, and vitamin B12 defeciency

Differentiating Myelodysplastic Syndrome from other Diseases

ABBREVIATIONS

EPO: Erythropoietin, FISH: Fluorescence in situ hybridization, Hb: Hemoglobin, LAD: Leukocyte alkaline dehydrgenase, LAP: Leukocyte alkaline phosphatase, LDH: Lactate dehydrogenase, LFTs: Liver function tests, NL: Normal, PCR: Polymerase chain reaction, Plt: Platelet, PUD: Peptic ulcer disease, RFTs: Renal function tests, WBCs: White blood cells.

Disease Clinical manifestations Diagnosis Other features
Symptoms Signs CBC & Peripheral smear Bone marrow biopsy Other investigations
WBCs Hb Plt
WBC Blasts Left
shift
Baso-
phils
Eosino-
phils
Mono-
cytes
Myelodysplastic syndromes
(MDS)[1][2]
Variable -
  • Leukemia transformation
  • Acquired pseudo-Pelger-Huët anomaly
Chronic myeloid leukemia
(CML)[3][4]
<2% + NL
Polycythemia vera
(PV)[5][6][7][8]
  • Constitutional
NL or ↑ None - ↑ or ↓ NL or ↑ NL ↑↑ NL
  • Hypercellularity for age with tri-lineage growth
Primary myelofibrosis (PMF)[9][10][11][12] Erythroblasts - Absent NL NL
  • Variable with fibrosis or hypercellularity
Disease Symptoms Sign WBC Blasts Left
shift
Baso-
phils
Eosino-
phils
Mono-
cytes
Hb Plt Bone marrow biopsy Other investigations Other features
Essential thrombocythemia (ET)[13][14][15]

NL or ↑

None

-

↓ or absent

NL

NL

↑↑

  • Normal/Hypercellular
Myelodysplastic
/myeloproliferative
neoplasms
(MDS/MPN)
Chronic myelomonocytic leukemia (CMML)[16]
[17][18]
< 20% NL ↑↑
  • Overlapping of both, MDS and MPN
  • Absolute monocytosis > 1 × 109/L (defining feature)
  • MD-CMML:WBC ≤ 13 × 109/L (FAB)
  •  MP-CMML:WBC > 13 × 109/L (FAB)
Atypical chronic myeloid leukemia (aCML), BCR-ABL1-[19][20] <20% + <2% of WBCs N/A N/A
Juvenile myelomonocytic leukemia (JMML)[21][22] N/A N/A N/A
MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)[23][24][25]
  • Variable
NL or ↑ NL - NL N/A N/A
Disease Symptoms Sign WBC Blasts Left
shift
Baso-
phils
Eosino-
phils
Mono-
cytes
Hb Plt Bone marrow biopsy Other investigations Other features
Chronic neutrophilic leukemia (CNL)[26][27][28] Minimal + NL NL NL
Chronic eosinophilic leukemia,
not otherwise specified
(NOS)[29][30][31][32]
Present + ↑↑
MPN,
unclassifiable
Variable ± ↑ or ↓ ↑ or ↓ ↑ or ↓
Mastocytosis[33][34][35][36]
  • Constitutional
None - NL NL ↓ or ↑
Myeloid/lymphoid neoplasms
with eosinophilia and rearrangement
of PDGFRA, PDGFRB, or FGFR1,
or with PCM1-JAK2[37][38][39][40]
NL - NL NL
  • FISH shows t(8;13) and t(8;22)
Disease Symptoms Sign WBC Blasts Left
shift
Baso-
phils
Eosino-
phils
Mono-
cytes
Hb Plt Bone marrow biopsy Other investigations Other features
B-lymphoblastic leukemia/lymphoma[41][42] NL or ↑ >25% N/A ↑ or ↓ ↑ or ↓ ↑ or ↓
Acute myeloid leukemia (AML)
and related neoplasms[43][44]
NL or ↑ N/A ↑ or ↓ ↑ or ↓ ↑ or ↓

with dysplasia

Blastic plasmacytoid
dendritic cell neoplasm
[45][46][47][48]
NL NL NL NL
Disease Symptoms Sign WBC Blasts Left
shift
Baso-
phils
Eosino-
phils
Mono-
cytes
Hb Plt Bone marrow biopsy Other investigations Other features
T-lymphoblastic leukemia/
lymphoma
T-lymphoblastic leukemia/
lymphoma[49][50][51]
>25% blasts (Leukemia)

<25% blasts (Lymphoma)

± ↑ or ↓ ↑ or ↓ ↑ or ↓
  • Hypercelluarity with increased T cells precursors
Provisional entity: Natural killer (NK) cell lymphoblastic leukemia/lymph[52] ± ↑ or ↓ ↑ or ↓ ↑ or ↓
  • N/A
Provisional entity: Early T-cell precursor lymphoblastic leukemia[53][54] ± ↑ or ↓ ↑ or ↓ ↑ or ↓
  • Hypercelluarity with increased T cells precursors

Differentiating myelodysplastic syndrome from other causes of macrocytic anemia

Disease Genetics Clinical manifestation Lab findings
History Symptoms Signs Hemolysis Intrinsic/Extrinsic Hb concentration MCV RDW Reticulocytosis Haptoglobin levels Hepcidin Iron studies Specific finding on blood smear
Serum iron Serum Tfr level Transferrin or TIBC Ferritin Transferrin saturation
Folate deficiency[55]
  • Impaired DNA synthesis
Anisochromic Macrocytic Nl Nl
Vitamin B12 deficiency[56] Anisochromic Macrocytic Nl Nl
Orotic aciduria[57]
  • Neurological manifestation
Anisochromic Macrocytic Nl Nl NA
Fanconi anemia[58]
  • Significant for bilateral short thumbs
Anisochromic Macrocytic Nl Nl
Disease Genetics History Symptoms Signs Hemolysis Intrinsic/Extrinsic Hb concentration MCV RDW Reticulocytosis Haptoglobin levels Hepcidin Serum iron Serum Tfr level IBC Ferritin Transferrin saturation Specific finding on blood smear
Diamond-Blackfan anemia[59] Mutations in:
  • RPL5
  • RPL11
  • RPL35A
  • RPS7
  • RPS10
  • RPS17
  • RPS19
  • RPS24
  • RPS26
Anisochromic Macrocytic Nl Nl Nl NA
Liver disease[60]
  • Hepatitis
  • Binge drinking
  • Gall bladder disease
Anisochromic Macrocytic Nl Nl
Alcoholism[61] Anisochromic Macrocytic Nl Nl
Disease Genetics History Symptoms Signs Hemolysis Intrinsic/Extrinsic Hb concentration MCV RDW Reticulocytosis Haptoglobin levels Hepcidin Serum iron Serum Tfr level IBC Ferritin Transferrin saturation Specific finding on blood smear

Differentiating myelodysplastic syndrome from other causes of thrombocytopenia

Condition Etiology Mechanism Inherited Acquried Clinical manifestations Para−clinical findings Gold standard Associated findings
Demography History Symptoms Signs
Lab Findings
Fever Rash Bleeding BP Splenomegaly Jaundice Other CBC PBS Bone marrow exam Other
Decreased platelet production Platelet destruction in blood Platelet destruction in spleen Plt HB WBC
Bone marrow disorders Myelodysplastic syndromes[62]
  • Unknown
  • Mutation
+ ± + Elderly Exposure to + Petechiae, purpura, diffuse erythematous rash + Nl + + Nl Bone marrow examination + clinical manifestation
Aplastic anemia[63] + ± ± Biphasic (the young and the elderly) + Nl
  • Elevated PT/PTT
Bone marrow examination +

laboratory findings

Acute leukemia[64][65] + + ± ± AML in adults
  • Exposure to chemicals
  • Radiation
  • Pre-existent blood disorders
± Petechiae + Nl ±
  • Blast cells
Bone marrow examination
Paroxysmal nocturnal hemoglobinuria (PNH)[66]
  • Mutations
+ + + Any age

(usually younger adults)

Nl ↓/Nl ↓/Nl
  • Hypocellular marrow in certain stages of the disease
Flow cytometry
Condition Etiology Decreased platelet production Platelet destruction in blood Platelet destruction in spleen Inherited Acquried Demography History Fever Rash Bleeding BP Splenomegaly Jaundice Other signs Plt HB WBC PBS Bone marrow exam UA Gold standard Associated findings
Thrombotic microangiopathy (TMA) Thrombotic thrombocytopenic purpura (TTP)[67]
  • Deficiency of, or antibodies to, the metalloprotease ADAMTS13
+ ± + Any age
  • Neurologic manifestations
  • Fatigue due to anemia
+ Petechiae Not common Nl or ↑ + Nl

or ↑

  • Fragmented RBCs
NA Laboratory findings
Hemolytic uremic syndrome (HUS)[68] + ± + Children
  • Exposure to contaminated water or milk
  • Consuming undercooked ground beef
+ Petechiae + Nl

or ↑

  • Fragmented RBCs
NA Laboratory findings
DIC[69][70]
  • Overstimulation of the coagulation system
+ + + Any age + + + + ↓↓ Clinical manifestation + laboratory findings
Nutrient deficiencies Folate, vitamin B12, copper deficiencies[71][72]
  • Decreased platelet production
+ + Any age
  • Malnutrition
  • Alcohol use
Nl Nl Nl Laboratory findings
Condition Etiology Decreased platelet production Platelet destruction in blood Platelet destruction in spleen Inherited Acquried Demography History Fever Rash Bleeding BP Splenomegaly Jaundice Other signs Plt HB WBC PBS Bone marrow exam UA Gold standard Associated findings
Congenital platelet disorders[73][74][75] MYH9-related disorders[76] + + Any age, very rare
  • Positive family history
+ Nl Nl
  • Döhle body-like inclusions in peripheral blood neutrophils
NA Nl Genetic study
Bernard-Soulier syndrome[77]
  • Absence of Gp Ib-IX-V
+ + Children, rare
  • Positive family history
+ Nl Nl Nl Nl Flow cytometry
Gray platelet syndrome[78] + + Rare
  • Positive family history
+

Mucocutaneous

Nl + Nl Nl Nl Genetic study
Wiskott-Aldrich syndrome[79] + + Rare
  • Positive family history
+ Nl Bloody diarrhea Nl Nl Nl Genetic study
Thrombocytopenia with absent radius (TAR) syndrome[80] + + Children
  • Positive family history
+ + Nl Nl Nl or ↑ Nl Evidence of absent radius

+

Laboratory findings

  • Cow's milk allergy
  • Various other anomalies
Fechtner syndrome[81]
  • Mutation of chromosome 22q11-13
+ + Children
  • Positive family history

petechia

+ Mucocutaneous Nl
  • Hearing loss
  • Eye abnormalities
Nl Nl or ↑ NA Clinical manifestation + genetic study
Von Willebrand disease[82]
  • VWF deficiency/dysfunction
+ + Rarely More common with O blood type
  • Positive family history
+ Nl/ ↓ Nl/↓ Nl NA Laboratory findings
  • Lifelong bleeding disorder
Condition Etiology Decreased platelet production Platelet destruction in blood Platelet destruction in spleen Inherited Acquried Demography History Fever Rash Bleeding BP Splenomegaly Jaundice Other signs Plt HB WBC PBS Bone marrow exam UA Gold standard Associated findings
ITP[83] + + + Any age

petechia

+ Mucocutaneous Nl ↓↓↓ Nl Nl Nl Nl Diagnosis of exclusion
  • Spontaneous remission
Systemic lupus erythematosus[84] + + Young women, more prevalent in Africans and Asians + Malar rash, generalized maculopapular rash, discoid rash +

Hemoptysis

Nl or ↑ + + Clinical manifestation + serology
Antiphospholipid syndrome[85]
  • Autoantibody-mediated syndrome
+ + + Middle aged women, more in African American and Hispanic population Nl Nl Clinical manifestation + repeated positive tests of aPL
Felty's syndrome[86] + + ± + Rare, young women Nl +
  • Lymphadenopathy
Nl Nl Clinical manifestation
Condition Etiology Decreased platelet production Platelet destruction in blood Platelet destruction in spleen Inherited Acquried Demography History Fever Rash Bleeding BP Splenomegaly Jaundice Other signs Plt HB WBC PBS Bone marrow exam UA Gold standard Associated findings
Bacterial infections Sepsis[87] + + + Any + ± Nl to ↓ ± ↓/↑ Nl ↑↑ NA
  • Elevated PT/PTT
Clinical manifestation + culture
  • Associated with ↑ mortality
Helicobacter pylori[88]
  • Immune thrombocytopenia
+ + Any Nl Nl Nl NA Nl Clinical manifestation + culture
Tick-borne infection[89]
  • Immune thrombocytopenia
+ + Endemic area like China, Japan, and Korea
  • Being bitten by a tick
+ ± Nl to ↓ ± ± Nl NA PCR
Viral infections HIV[90]
  • Immune thrombocytopenia
+ + + + Any
  • High risk behaviors
  • Close contact
+ ± Nl to ↓ ± ± Isolation of HIV
Other viruses such as rubella, mumps, varicella, parvovirus, hepatitis C, & Epstein-Barr virus[91]
  • Immune thrombocytopenia
+ + Any
  • High risk behaviors
  • Close contact
+ Nl ± ± Clinical manifestation + lab tests
Parasitic infections Malaria[92]
  • Unknown
  • Immune thrombocytopenia
+ + Endemic area
  • Being bitten by a mosquito
+ ± Nl to ↓ ± ± Clinical manifestation + microscopic examination of blood smear
Babesiosis[93]
  • Unknown
  • Immune thrombocytopenia
+ + Rare + ± Nl to ↓ ± ± Clinical manifestation + microscopic examination of blood smear
Condition Etiology Decreased platelet production Platelet destruction in blood Platelet destruction in spleen Inherited Acquried Demography History Fever Rash Bleeding BP Splenomegaly Jaundice Other signs Plt HB WBC PBS Bone marrow exam UA Gold standard Associated findings
Antibiotics/

Antiepileptic[94]

  • Occurrence of drug-dependent, platelet-reactive antibodies
+ + + Any
  • Drug ingestion or injection
Nl ↓↓ Nl NA Nl Clinical manifestation + exclusion of the other causes NA
Heparin-induced thrombocytopenia[95]
  • Anti-heparin/PF4 antibody
+ + Any
  • Heparin injection
  • Necrotic skin lesions
Nl Nl Nl NA Nl ELISA
Cytotoxic chemotherapy[96] + + Patients with malignancy
  • Drug ingestion or injection
  • Cancer
Nl
  • Megakaryocytic hypoplasia or aplasia
Clinical manifestation + exclusion of the other causes
Radiation therapy[97] + + Patients with malignancy + Nl
  • Megakaryocytic hypoplasia or aplasia
Clinical manifestation + exclusion of the other causes
Chronic liver disease[98] + + Any + + + Nl NA Biopsy
Portal hypertension[99] + + Any + + + Nl NA
  • Elevated PT/PTT
Clinical manifestation
Condition Etiology Decreased platelet production Platelet destruction in blood Platelet destruction in spleen Inherited Acquried Demography History Fever Rash Bleeding BP Splenomegaly Jaundice Other signs Plt HB WBC PBS Bone marrow exam UA Gold standard Associated findings
Giant capillary hemangioma (Kasabach-Merritt syndrome)[100][101] + + Infants Intralesional bleeding Nl Visceral hemangiomas ↓↓ ↓↓ Nl Normocytic normochromic erythrocytes and markedly reduced platelets Normal erythropoiesis, myelopoiesis, and megakaryocytic hyperplasia Biopsy
  • Kaposiform hemangioendothelioma
  • Tufted angioma
Cardiopulmonary bypass[102] + + Elderly + Nl or ↑ Nl Normocytic normochromic erythrocytes and markedly reduced platelets NA Clinical manifestation
Alcohol[103] + + + Any Nl + + Cytopenia, macrocytosis Cytopenia, macrocytosis
  • Elevated PT/PTT
Clinical manifestation
Post-transfusion purpura[104][105] + + Women + ↓↓↓ Nl Nl NA Nl Positive circulating alloantibody to a common platelet antigen
  • Severe but rare reaction
Gestational thrombocytopenia[106]
  • Might be physiologic adaptation of pregnancy
+ Pregnant women
  • Positive history of mild thrombocytopenia
Nl Nl Nl Nl NA Nl Diagnosis of exclusion
  • Self-limited condition
HELLP syndrome[107][108]
  • Unknown
+ + Pregnant > 25 years + + Nl Schistocytes NA Proteinuria Lab abnormalities
Idiopathic cyclic thrombocytopenia[109] + + + Females with the median age of onset 35 years
  • Misdiagnosed as ITP with uniformly poor responses
Minor mucocutaneous bleeding Nl Nl Nl Reduced platelets and megakaryocytes Megakaryocytic hypoplasia or aplasia Nl Diagnosis of exclusion
Pseudothrombocytopenia[110] + Rare Collected sample in EDTA anticoagulant Nl Nl Nl Low platelet count and platelet clumps Low platelet count and platelet clumps Nl Repeat collecting sample in a heparin tube Nl
Condition Etiology Decreased platelet production Platelet destruction in blood Platelet destruction in spleen Inherited Acquried Demography History Fever Rash Bleeding BP Splenomegaly Jaundice Other signs Plt HB WBC PBS Bone marrow exam UA Gold standard Associated findings

References

  1. Germing U, Kobbe G, Haas R, Gattermann N (November 2013). "Myelodysplastic syndromes: diagnosis, prognosis, and treatment". Dtsch Arztebl Int. 110 (46): 783–90. doi:10.3238/arztebl.2013.0783. PMC 3855821. PMID 24300826.
  2. Gangat N, Patnaik MM, Tefferi A (January 2016). "Myelodysplastic syndromes: Contemporary review and how we treat". Am. J. Hematol. 91 (1): 76–89. doi:10.1002/ajh.24253. PMID 26769228.
  3. Savage DG, Szydlo RM, Goldman JM (January 1997). "Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period". Br. J. Haematol. 96 (1): 111–6. PMID 9012696.
  4. Thompson PA, Kantarjian HM, Cortes JE (October 2015). "Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015". Mayo Clin. Proc. 90 (10): 1440–54. doi:10.1016/j.mayocp.2015.08.010. PMC 5656269. PMID 26434969.
  5. Vannucchi AM, Guglielmelli P, Tefferi A (March 2018). "Polycythemia vera and essential thrombocythemia: algorithmic approach". Curr. Opin. Hematol. 25 (2): 112–119. doi:10.1097/MOH.0000000000000402. PMID 29194068.
  6. Pillai AA, Babiker HM. PMID 30252337. Missing or empty |title= (help)
  7. Tefferi A, Barbui T (January 2019). "Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management". Am. J. Hematol. 94 (1): 133–143. doi:10.1002/ajh.25303. PMID 30281843.
  8. Rumi E, Cazzola M (February 2017). "Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms". Blood. 129 (6): 680–692. doi:10.1182/blood-2016-10-695957. PMC 5335805. PMID 28028026.
  9. Cervantes F, Correa JG, Hernandez-Boluda JC (May 2016). "Alleviating anemia and thrombocytopenia in myelofibrosis patients". Expert Rev Hematol. 9 (5): 489–96. doi:10.1586/17474086.2016.1154452. PMID 26891375.
  10. Hoffman, Ronald (2018). Hematology : basic principles and practice. Philadelphia, PA: Elsevier. ISBN 9780323357623.
  11. Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W (March 2007). "Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF)". Pathol. Biol. 55 (2): 92–104. doi:10.1016/j.patbio.2006.06.002. PMID 16919893.
  12. Hoffman, Ronald (2018). Hematology : basic principles and practice. Philadelphia, PA: Elsevier. ISBN 9780323357623.
  13. Schmoldt A, Benthe HF, Haberland G (1975). "Digitoxin metabolism by rat liver microsomes". Biochem Pharmacol. 24 (17): 1639–41. PMID http://dx.doi.org/10.1182/blood-2007-04-083501 Check |pmid= value (help).
  14. Daniel A. Arber, Attilio Orazi, Robert Hasserjian, Jurgen Thiele, Michael J. Borowitz, Michelle M. Le Beau, Clara D. Bloomfield, Mario Cazzola & James W. Vardiman (2016). "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. 127 (20): 2391–2405. doi:10.1182/blood-2016-03-643544. PMID 27069254. Unknown parameter |month= ignored (help)
  15. A. Tefferi, R. Fonseca, D. L. Pereira & H. C. Hoagland (2001). "A long-term retrospective study of young women with essential thrombocythemia". Mayo Clinic proceedings. 76 (1): 22–28. doi:10.4065/76.1.22. PMID 11155408. Unknown parameter |month= ignored (help)
  16. Patnaik MM, Tefferi A (June 2016). "Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management". Am. J. Hematol. 91 (6): 631–42. doi:10.1002/ajh.24396. PMID 27185207.
  17. Parikh SA, Tefferi A (June 2012). "Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management". Am. J. Hematol. 87 (6): 610–9. doi:10.1002/ajh.23203. PMID 22615103.
  18. Benton CB, Nazha A, Pemmaraju N, Garcia-Manero G (August 2015). "Chronic myelomonocytic leukemia: Forefront of the field in 2015". Crit. Rev. Oncol. Hematol. 95 (2): 222–42. doi:10.1016/j.critrevonc.2015.03.002. PMC 4859155. PMID 25869097.
  19. Dao KH, Tyner JW (2015). "What's different about atypical CML and chronic neutrophilic leukemia?". Hematology Am Soc Hematol Educ Program. 2015: 264–71. doi:10.1182/asheducation-2015.1.264. PMC 5266507. PMID 26637732.
  20. Muramatsu H, Makishima H, Maciejewski JP (February 2012). "Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions". Semin. Oncol. 39 (1): 67–73. doi:10.1053/j.seminoncol.2011.11.004. PMC 3523950. PMID 22289493.
  21. Aricò M, Biondi A, Pui CH (July 1997). "Juvenile myelomonocytic leukemia". Blood. 90 (2): 479–88. PMID 9226148.
  22. Hasle H (March 1994). "Myelodysplastic syndromes in childhood--classification, epidemiology, and treatment". Leuk. Lymphoma. 13 (1–2): 11–26. doi:10.3109/10428199409051647. PMID 8025513.
  23. Patnaik MM, Tefferi A (March 2017). "Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management". Am. J. Hematol. 92 (3): 297–310. doi:10.1002/ajh.24637. PMID 28188970.
  24. Alshaban A, Padilla O, Philipovskiy A, Corral J, McAlice M, Gaur S (2018). "Lenalidomide induced durable remission in a patient with MDS/MPN-with ring sideroblasts and thrombocytosis with associated 5q- syndrome". Leuk Res Rep. 10: 37–40. doi:10.1016/j.lrr.2018.08.001. PMID 30186759.
  25. Bouchla A, Papageorgiou SG, Tsakiraki Z, Glezou E, Pavlidis G, Stavroulaki G, Bazani E, Foukas P, Pappa V (2018). "Plasmablastic Lymphoma in an Immunocompetent Patient with MDS/MPN with Ring Sideroblasts and Thrombocytosis-A Case Report". Case Rep Hematol. 2018: 2525070. doi:10.1155/2018/2525070. PMC 6247723. PMID 30524760.
  26. Szuber N, Tefferi A (February 2018). "Chronic neutrophilic leukemia: new science and new diagnostic criteria". Blood Cancer J. 8 (2): 19. doi:10.1038/s41408-018-0049-8. PMC 5811432. PMID 29440636.
  27. Maxson JE, Tyner JW (February 2017). "Genomics of chronic neutrophilic leukemia". Blood. 129 (6): 715–722. doi:10.1182/blood-2016-10-695981. PMC 5301820. PMID 28028025.
  28. Menezes J, Cigudosa JC (2015). "Chronic neutrophilic leukemia: a clinical perspective". Onco Targets Ther. 8: 2383–90. doi:10.2147/OTT.S49688. PMC 4562747. PMID 26366092.
  29. Vidyadharan S, Joseph B, Nair SP (2016). "Chronic Eosinophilic Leukemia Presenting Predominantly with Cutaneous Manifestations". Indian J Dermatol. 61 (4): 437–9. doi:10.4103/0019-5154.185716. PMC 4966405. PMID 27512192.
  30. Hofmans M, Delie A, Vandepoele K, Van Roy N, Van der Meulen J, Philippé J, Moors I (2018). "A case of chronic eosinophilic leukemia with secondary transformation to acute myeloid leukemia". Leuk Res Rep. 9: 45–47. doi:10.1016/j.lrr.2018.04.001. PMC 5993353. PMID 29892549.
  31. Yamada Y, Rothenberg ME, Cancelas JA (2006). "Current concepts on the pathogenesis of the hypereosinophilic syndrome/chronic eosinophilic leukemia". Transl Oncogenomics. 1: 53–63. PMC 3642145. PMID 23662039.
  32. Kim TH, Gu HJ, Lee WI, Lee J, Yoon HJ, Park TS (September 2016). "Chronic eosinophilic leukemia with FIP1L1-PDGFRA rearrangement". Blood Res. 51 (3): 204–206. doi:10.5045/br.2016.51.3.204. PMID 27722133.
  33. Carter MC, Metcalfe DD, Komarow HD (February 2014). "Mastocytosis". Immunol Allergy Clin North Am. 34 (1): 181–96. doi:10.1016/j.iac.2013.09.001. PMC 3863935. PMID 24262698.
  34. Macri A, Cook C. PMID 29494109. Missing or empty |title= (help)
  35. Lladó AC, Mihon CE, Silva M, Galzerano A (2014). "Systemic mastocytosis - a diagnostic challenge". Rev Bras Hematol Hemoter. 36 (3): 226–9. doi:10.1016/j.bjhh.2014.03.003. PMC 4109736. PMID 25031064.
  36. Valent P, Akin C, Metcalfe DD (March 2017). "Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts". Blood. 129 (11): 1420–1427. doi:10.1182/blood-2016-09-731893. PMC 5356454. PMID 28031180.
  37. Kumar, Kirthi R.; Chen, Weina; Koduru, Prasad R.; Luu, Hung S. (2015). "Myeloid and Lymphoid Neoplasm With Abnormalities of FGFR1 Presenting With Trilineage Blasts and RUNX1 Rearrangement". American Journal of Clinical Pathology. 143 (5): 738–748. doi:10.1309/AJCPUD6W1JLQQMNA. ISSN 1943-7722.
  38. Paolo Strati, Guilin Tang, Dzifa Y. Duose, Saradhi Mallampati, Rajyalakshmi Luthra, Keyur P. Patel, Mohammad Hussaini, Abu-Sayeef Mirza, Rami S. Komrokji, Stephen Oh, John Mascarenhas, Vesna Najfeld, Vivek Subbiah, Hagop Kantarjian, Guillermo Garcia-Manero, Srdan Verstovsek & Naval Daver (2018). "Myeloid/lymphoid neoplasms with FGFR1 rearrangement". Leukemia & lymphoma. 59 (7): 1672–1676. doi:10.1080/10428194.2017.1397663. PMID 29119847. Unknown parameter |month= ignored (help)
  39. Ximena Montenegro-Garreaud, Roberto N. Miranda, Alexandra Reynolds, Guilin Tang, Sa A. Wang, Mariko Yabe, Wei Wang, Lianghua Fang, Carlos E. Bueso-Ramos, Pei Lin, L. Jeffrey Medeiros & Xinyan Lu (2017). "Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase". Human pathology. 65: 147–156. doi:10.1016/j.humpath.2017.05.008. PMID 28551329. Unknown parameter |month= ignored (help)
  40. Paola Villafuerte-Gutierrez, Montserrat Lopez Rubio, Pilar Herrera & Eva Arranz (2018). "A Case of Myeloproliferative Neoplasm with BCR-FGFR1 Rearrangement: Favorable Outcome after Haploidentical Allogeneic Transplantation". Case reports in hematology. 2018: 5724960. doi:10.1155/2018/5724960. PMID 30647980.
  41. Kamiya-Matsuoka C, Garciarena P, Amin HM, Tremont-Lukats IW, de Groot JF (December 2013). "B lymphoblastic leukemia/lymphoma presenting as seventh cranial nerve palsy". Neurol Clin Pract. 3 (6): 532–534. doi:10.1212/CPJ.0b013e3182a78ef0. PMC 6082360. PMID 30107017.
  42. Zhang X, Rastogi P, Shah B, Zhang L (September 2017). "B lymphoblastic leukemia/lymphoma: new insights into genetics, molecular aberrations, subclassification and targeted therapy". Oncotarget. 8 (39): 66728–66741. doi:10.18632/oncotarget.19271. PMC 5630450. PMID 29029550.
  43. Islam A, Catovsky D, Goldman JM, Galton DA (September 1985). "Bone marrow biopsy changes in acute myeloid leukaemia. I: Observations before chemotherapy". Histopathology. 9 (9): 939–57. PMID 3864727.
  44. Orazi A (2007). "Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases". Pathobiology. 74 (2): 97–114. doi:10.1159/000101709. PMID 17587881.
  45. F. Julia, T. Petrella, M. Beylot-Barry, M. Bagot, D. Lipsker, L. Machet, P. Joly, O. Dereure, M. Wetterwald, M. d'Incan, F. Grange, J. Cornillon, G. Tertian, E. Maubec, P. Saiag, S. Barete, I. Templier, F. Aubin & S. Dalle (2013). "Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients". The British journal of dermatology. 169 (3): 579–586. doi:10.1111/bjd.12412. PMID 23646868. Unknown parameter |month= ignored (help)
  46. Livio Pagano, Caterina Giovanna Valentini, Alessandro Pulsoni, Simona Fisogni, Paola Carluccio, Francesco Mannelli, Monia Lunghi, Gianmatteo Pica, Francesco Onida, Chiara Cattaneo, Pier Paolo Piccaluga, Eros Di Bona, Elisabetta Todisco, Pellegrino Musto, Antonio Spadea, Alfonso D'Arco, Stefano Pileri, Giuseppe Leone, Sergio Amadori & Fabio Facchetti (2013). "Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study". Haematologica. 98 (2): 239–246. doi:10.3324/haematol.2012.072645. PMID 23065521. Unknown parameter |month= ignored (help)
  47. Joseph D. Khoury (2018). "Blastic Plasmacytoid Dendritic Cell Neoplasm". Current hematologic malignancy reports. 13 (6): 477–483. doi:10.1007/s11899-018-0489-z. PMID 30350260. Unknown parameter |month= ignored (help)
  48. Shinichiro Sukegawa, Mamiko Sakata-Yanagimoto, Ryota Matsuoka, Haruka Momose, Yusuke Kiyoki, Masayuki Noguchi, Naoya Nakamura, Rei Watanabe, Manabu Fujimoto, Yasuhisa Yokoyama, Hidekazu Nishikii, Takayasu Kato, Manabu Kusakabe, Naoki Kurita, Naoshi Obara, Yuichi Hasegawa & Shigeru Chiba (2018). "[Blastic plasmacytoid dendritic cell neoplasm accompanied by chronic myelomonocytic leukemia successfully treated with azacitidine]". [[[Rinsho ketsueki] The Japanese journal of clinical hematology]]. 59 (12): 2567–2573. doi:10.11406/rinketsu.59.2567. PMID 30626790.
  49. You MJ, Medeiros LJ, Hsi ED (September 2015). "T-lymphoblastic leukemia/lymphoma". Am. J. Clin. Pathol. 144 (3): 411–22. doi:10.1309/AJCPMF03LVSBLHPJ. PMID 26276771.
  50. Patel KJ, Latif SU, de Calaca WM (March 2009). "An unusual presentation of precursor T cell lymphoblastic leukemia/lymphoma with cholestatic jaundice: case report". J Hematol Oncol. 2: 12. doi:10.1186/1756-8722-2-12. PMC 2663564. PMID 19284608.
  51. Elreda L, Sandhu M, Sun X, Bekele W, Cohen AJ, Shah M (2014). "T-cell lymphoblastic leukemia/lymphoma: relapse 16 years after first remission". Case Rep Hematol. 2014: 359158. doi:10.1155/2014/359158. PMC 4005062. PMID 24822133.
  52. Sedick Q, Alotaibi S, Alshieban S, Naheet KB, Elyamany G (2017). "Natural Killer Cell Lymphoblastic Leukaemia/Lymphoma: Case Report and Review of the Recent Literature". Case Rep Oncol. 10 (2): 588–595. doi:10.1159/000477843. PMID 28868017.
  53. Jain N, Lamb AV, O'Brien S, Ravandi F, Konopleva M, Jabbour E, Zuo Z, Jorgensen J, Lin P, Pierce S, Thomas D, Rytting M, Borthakur G, Kadia T, Cortes J, Kantarjian HM, Khoury JD (April 2016). "Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype". Blood. 127 (15): 1863–9. doi:10.1182/blood-2015-08-661702. PMC 4915808. PMID 26747249.
  54. Haydu JE, Ferrando AA (July 2013). "Early T-cell precursor acute lymphoblastic leukaemia". Curr. Opin. Hematol. 20 (4): 369–73. doi:10.1097/MOH.0b013e3283623c61. PMC 3886681. PMID 23695450.
  55. Koike H, Takahashi M, Ohyama K, Hashimoto R, Kawagashira Y, Iijima M, Katsuno M, Doi H, Tanaka F, Sobue G (March 2015). "Clinicopathologic features of folate-deficiency neuropathy". Neurology. 84 (10): 1026–33. doi:10.1212/WNL.0000000000001343. PMID 25663227.
  56. Hunt A, Harrington D, Robinson S (September 2014). "Vitamin B12 deficiency". BMJ. 349: g5226. PMID 25189324.
  57. Grohmann K, Lauffer H, Lauenstein P, Hoffmann GF, Seidlitz G (April 2015). "Hereditary orotic aciduria with epilepsy and without megaloblastic anemia". Neuropediatrics. 46 (2): 123–5. doi:10.1055/s-0035-1547341. PMID 25757096.
  58. Alter BP (2014). "Fanconi anemia and the development of leukemia". Best Pract Res Clin Haematol. 27 (3–4): 214–21. doi:10.1016/j.beha.2014.10.002. PMC 4254647. PMID 25455269.
  59. Vlachos A, Blanc L, Lipton JM (June 2014). "Diamond Blackfan anemia: a model for the translational approach to understanding human disease". Expert Rev Hematol. 7 (3): 359–72. doi:10.1586/17474086.2014.897923. PMID 24665981.
  60. Marks PW (July 2013). "Hematologic manifestations of liver disease". Semin. Hematol. 50 (3): 216–21. doi:10.1053/j.seminhematol.2013.06.003. PMID 23953338.
  61. Yokoyama A, Yokoyama T, Brooks PJ, Mizukami T, Matsui T, Kimura M, Matsushita S, Higuchi S, Maruyama K (May 2014). "Macrocytosis, macrocytic anemia, and genetic polymorphisms of alcohol dehydrogenase-1B and aldehyde dehydrogenase-2 in Japanese alcoholic men". Alcohol. Clin. Exp. Res. 38 (5): 1237–46. doi:10.1111/acer.12372. PMID 24588059.
  62. Natelson, Ethan A.; Pyatt, David (2013). "Acquired Myelodysplasia or Myelodysplastic Syndrome: Clearing the Fog". Advances in Hematology. 2013: 1–11. doi:10.1155/2013/309637. ISSN 1687-9104.
  63. Townsley, Danielle M.; Desmond, Ronan; Dunbar, Cynthia E.; Young, Neal S. (2013). "Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes". International Journal of Hematology. 98 (1): 48–55. doi:10.1007/s12185-013-1352-6. ISSN 0925-5710.
  64. Oshima, Yasuo; Yuji, Koichiro; Tanimoto, Tetsuya; Hinomura, Yasushi; Tojo, Arinobu (2013). "Association between Acute Myelogenous Leukemia and Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia". Internal Medicine. 52 (19): 2193–2201. doi:10.2169/internalmedicine.52.0324. ISSN 0918-2918.
  65. Oshima Y, Yuji K, Tanimoto T, Hinomura Y, Tojo A (2013). "Association between acute myelogenous leukemia and thrombopoietin receptor agonists in patients with immune thrombocytopenia". Intern. Med. 52 (19): 2193–201. PMID 24088751.
  66. Brodsky RA (2014). "Paroxysmal nocturnal hemoglobinuria". Blood. 124 (18): 2804–11. doi:10.1182/blood-2014-02-522128. PMC 4215311. PMID 25237200.
  67. Noris M, Mescia F, Remuzzi G (November 2012). "STEC-HUS, atypical HUS and TTP are all diseases of complement activation". Nat Rev Nephrol. 8 (11): 622–33. doi:10.1038/nrneph.2012.195. PMID 22986360.
  68. Conway EM (October 2015). "HUS and the case for complement". Blood. 126 (18): 2085–90. doi:10.1182/blood-2015-03-569277. PMID 26396094.
  69. Schwameis M, Schörgenhofer C, Assinger A, Steiner MM, Jilma B (April 2015). "VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP". Thromb. Haemost. 113 (4): 708–18. doi:10.1160/TH14-09-0731. PMC 4745134. PMID 25503977.
  70. Kitchens CS (2009). "Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC)". Hematology Am Soc Hematol Educ Program: 240–6. doi:10.1182/asheducation-2009.1.240. PMID 20008204.
  71. Clarke, V.; Weston-Smith, S. (2010). "Severe folate-deficiency pancytopenia". Case Reports. 2010 (oct18 2): bcr0320102851–bcr0320102851. doi:10.1136/bcr.03.2010.2851. ISSN 1757-790X.
  72. Blackmer AB, Bailey E (February 2013). "Management of copper deficiency in cholestatic infants: review of the literature and a case series". Nutr Clin Pract. 28 (1): 75–86. doi:10.1177/0884533612461531. PMID 23069991.
  73. Nurden AT, Freson K, Seligsohn U (2012). "Inherited platelet disorders". Haemophilia. 18 Suppl 4: 154–60. doi:10.1111/j.1365-2516.2012.02856.x. PMID 22726100.
  74. Balduini, Carlo L.; Savoia, Anna (2012). "Genetics of familial forms of thrombocytopenia". Human Genetics. 131 (12): 1821–1832. doi:10.1007/s00439-012-1215-x. ISSN 0340-6717.
  75. D'Andrea G, Chetta M, Margaglione M (2009). "Inherited platelet disorders: thrombocytopenias and thrombocytopathies". Blood Transfus. 7 (4): 278–92. doi:10.2450/2009.0078-08. PMC 2782805. PMID 20011639.
  76. Zhang S, Zhou X, Liu S, Bai T, Zhang Y, Wang J, Wang S, Zhang X, Wang B (2014). "MYH9-related disease: description of a large Chinese pedigree and a survey of reported mutations". Acta Haematol. 132 (2): 193–8. doi:10.1159/000356681. PMID 24643058.
  77. Berndt MC, Andrews RK (March 2011). "Bernard-Soulier syndrome". Haematologica. 96 (3): 355–9. doi:10.3324/haematol.2010.039883. PMC 3046265. PMID 21357716.
  78. Michelson AD (January 2013). "Gray platelet syndrome". Blood. 121 (2): 250. PMID 23427340.
  79. Candotti F (January 2018). "Clinical Manifestations and Pathophysiological Mechanisms of the Wiskott-Aldrich Syndrome". J. Clin. Immunol. 38 (1): 13–27. doi:10.1007/s10875-017-0453-z. PMID 29086100.
  80. Al-Qattan MM (November 2016). "The Pathogenesis of Radial Ray Deficiency in Thrombocytopenia-Absent Radius (TAR) Syndrome". J Coll Physicians Surg Pak. 26 (11): 912–916. doi:2476 Check |doi= value (help). PMID 27981927.
  81. Toren A, Amariglio N, Rozenfeld-Granot G, Simon AJ, Brok-Simoni F, Pras E, Rechavi G (December 1999). "Genetic linkage of autosomal-dominant Alport syndrome with leukocyte inclusions and macrothrombocytopenia (Fechtner syndrome) to chromosome 22q11-13". Am. J. Hum. Genet. 65 (6): 1711–7. doi:10.1086/302654. PMC 1288382. PMID 10577925.
  82. Langer F, Obser T, Oyen F, Spath B, Holstein K, Greinacher A, White JG, Budde U, Bokemeyer C, Schneppenheim R (April 2014). "Characterisation of the p.A1461D mutation causing von Willebrand disease type 2B with severe thrombocytopenia, circulating giant platelets, and defective α-granule secretion". Thromb. Haemost. 111 (4): 777–9. doi:10.1160/TH13-06-0462. PMID 24337418.
  83. Zufferey, Anne; Kapur, Rick; Semple, John (2017). "Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)". Journal of Clinical Medicine. 6 (2): 16. doi:10.3390/jcm6020016. ISSN 2077-0383.
  84. Abu-Hishmeh M, Sattar A, Zarlasht F, Ramadan M, Abdel-Rahman A, Hinson S, Hwang C (October 2016). "Systemic Lupus Erythematosus Presenting as Refractory Thrombotic Thrombocytopenic Purpura: A Diagnostic and Management Challenge. A Case Report and Concise Review of the Literature". Am J Case Rep. 17: 782–787. PMC 5083062. PMID 27777394.
  85. Artim-Esen, Bahar; Diz-Küçükkaya, Reyhan; İnanç, Murat (2015). "The Significance and Management of Thrombocytopenia in Antiphospholipid Syndrome". Current Rheumatology Reports. 17 (3). doi:10.1007/s11926-014-0494-8. ISSN 1523-3774.
  86. Chavalitdhamrong, Disaya; Molovic-Kokovic, Ana; Iliev, Andrey (2009). "Felty's Syndrome as an initial presentation of Rheumatoid Arthritis: a case report". Cases Journal. 2 (1): 206. doi:10.1186/1757-1626-2-206. ISSN 1757-1626.
  87. Wu, Qin; Ren, Jianan; Wu, Xiuwen; Wang, Gefei; Gu, Guosheng; Liu, Song; Wu, Yin; Hu, Dong; Zhao, Yunzhao; Li, Jieshou (2014). "Recombinant human thrombopoietin improves platelet counts and reduces platelet transfusion possibility among patients with severe sepsis and thrombocytopenia: A prospective study". Journal of Critical Care. 29 (3): 362–366. doi:10.1016/j.jcrc.2013.11.023. ISSN 0883-9441.
  88. Kuwana M (January 2014). "Helicobacter pylori-associated immune thrombocytopenia: clinical features and pathogenic mechanisms". World J. Gastroenterol. 20 (3): 714–23. doi:10.3748/wjg.v20.i3.714. PMC 3921481. PMID 24574745.
  89. Liu Q, He B, Huang SY, Wei F, Zhu XQ (August 2014). "Severe fever with thrombocytopenia syndrome, an emerging tick-borne zoonosis". Lancet Infect Dis. 14 (8): 763–772. doi:10.1016/S1473-3099(14)70718-2. PMID 24837566.
  90. Borges ÁH, Lundgren JD, Mocroft A (July 2015). "Thrombocytopenia and cancer risk during HIV infection". AIDS. 29 (11): 1425–7. doi:10.1097/QAD.0000000000000744. PMID 26098601.
  91. Saeed M, Dabbagh O, Al-Muhaizae M, Dhalaan H, Chedrawi A (November 2014). "Acute disseminated encephalomyelitis and thrombocytopenia following Epstein-Barr virus infection". J Coll Physicians Surg Pak. 24 Suppl 3: S216–8. doi:11.2014/JCPSP.S216S218 Check |doi= value (help). PMID 25518779.
  92. Rodriguez-Morales AJ, Giselle-Badillo A, Manrique-Castaño S, Yepes MC (2014). "Anemia and thrombocytopenia in Plasmodium vivax malaria is not unusual in patients from endemic and non-endemic settings". Travel Med Infect Dis. 12 (5): 549–50. doi:10.1016/j.tmaid.2014.07.006. PMID 25131143.
  93. Nackos E, DeSancho M (March 2014). "Anemia and thrombocytopenia: diagnosis from the blood smear". Blood. 123 (12): 1783. PMID 24783256.
  94. Visentin GP, Liu CY (August 2007). "Drug-induced thrombocytopenia". Hematol. Oncol. Clin. North Am. 21 (4): 685–96, vi. doi:10.1016/j.hoc.2007.06.005. PMC 1993236. PMID 17666285.
  95. Lovecchio, F. (2014). "Heparin-induced thrombocytopenia". Clinical Toxicology. 52 (6): 579–583. doi:10.3109/15563650.2014.917181. ISSN 1556-3650.
  96. Parameswaran, R.; Lunning, M.; Mantha, S.; Devlin, S.; Hamilton, A.; Schwartz, G.; Soff, G. (2014). "Romiplostim for management of chemotherapy-induced thrombocytopenia". Supportive Care in Cancer. 22 (5): 1217–1222. doi:10.1007/s00520-013-2074-2. ISSN 0941-4355.
  97. Bercovitz RS, Josephson CD (2012). "Thrombocytopenia and bleeding in pediatric oncology patients". Hematology Am Soc Hematol Educ Program. 2012: 499–505. doi:10.1182/asheducation-2012.1.499. PMID 23233625.
  98. Loffredo, Lorenzo; Violi, Francesco (2018). "Thrombopoietin receptor agonists and risk of portal vein thrombosis in patients with liver disease and thrombocytopenia: A meta-analysis". Digestive and Liver Disease. doi:10.1016/j.dld.2018.06.005. ISSN 1590-8658.
  99. Jia YP, Lu Q, Gong S, Ma BY, Wen XR, Peng YL, Lin L, Chen HY, Qiu L, Luo Y (September 2007). "Postoperative complications in patients with portal vein thrombosis after liver transplantation: evaluation with Doppler ultrasonography". World J. Gastroenterol. 13 (34): 4636–40. PMC 4611842. PMID 17729421.
  100. Lewis D, Vaidya R. Kasabach Merritt Syndrome. [Updated 2018 Jul 27]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-. Available from: https://www-ncbi-nlm-nih-gov.ezp-prod1.hul.harvard.edu/books/NBK519053/
  101. Vinod, Kolar Vishwanath; Johny, Joseph; Vadivelan, Mehalingam; Hamide, Abdoul (2017). "Kasabach-Merritt Syndrome in an adult". Turkish Journal of Hematology. doi:10.4274/tjh.2017.0429. ISSN 1300-7777.
  102. Ji, Sung-Mi; Kim, Sung-Hoon; Nam, Jae-Sik; Yun, Hye-Joo; Choi, Jeong-Hyun; Lee, Eun-Ho; Choi, In-Cheol (2015). "Predictive value of rotational thromboelastometry during cardiopulmonary bypass for thrombocytopenia and hypofibrinogenemia after weaning of cardiopulmonary bypass". Korean Journal of Anesthesiology. 68 (3): 241. doi:10.4097/kjae.2015.68.3.241. ISSN 2005-6419.
  103. Latvala J, Parkkila S, Niemelä O (April 2004). "Excess alcohol consumption is common in patients with cytopenia: studies in blood and bone marrow cells". Alcohol. Clin. Exp. Res. 28 (4): 619–24. PMID 15100613.
  104. McCrae, Keith R.; Herman, Jay H. (1996). "Posttransfusion purpura: Two unusual cases and a literature review". American Journal of Hematology. 52 (3): 205–211. doi:10.1002/(SICI)1096-8652(199607)52:3<205::AID-AJH13>3.0.CO;2-E. ISSN 0361-8609.
  105. Pavenski, Katerina; Webert, Kathryn E.; Goldman, Mindy (2008). "Consequences of transfusion of platelet antibody: a case report and literature review". Transfusion. 48 (9): 1981–1989. doi:10.1111/j.1537-2995.2008.01796.x. ISSN 0041-1132.
  106. Reese, Jessica A.; Peck, Jennifer D.; Deschamps, David R.; McIntosh, Jennifer J.; Knudtson, Eric J.; Terrell, Deirdra R.; Vesely, Sara K.; George, James N. (2018). "Platelet Counts during Pregnancy". New England Journal of Medicine. 379 (1): 32–43. doi:10.1056/NEJMoa1802897. ISSN 0028-4793.
  107. Barnhart, Lynette (2015). "HELLP Syndrome and the Effects on the Neonate". Neonatal Network. 34 (5): 269–273. doi:10.1891/0730-0832.34.5.269. ISSN 0730-0832.
  108. Haram, Kjell; Svendsen, Einar; Abildgaard, Ulrich (2009). "The HELLP syndrome: Clinical issues and management. A Review". BMC Pregnancy and Childbirth. 9 (1). doi:10.1186/1471-2393-9-8. ISSN 1471-2393.
  109. Go, Ronald S. (2005). "Idiopathic cyclic thrombocytopenia". Blood Reviews. 19 (1): 53–59. doi:10.1016/j.blre.2004.05.001. ISSN 0268-960X.
  110. Tan, Geok Chin; Stalling, Melissa; Dennis, Gretchen; Nunez, Maria; Kahwash, Samir B. (2016). "Pseudothrombocytopenia due to Platelet Clumping: A Case Report and Brief Review of the Literature". Case Reports in Hematology. 2016: 1–4. doi:10.1155/2016/3036476. ISSN 2090-6560.